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Abstract 
BACKGROUND: The aim of this study was to investigate how the national guidelines for 
the biological medicaments Tumor Necrosis Factor-alpha (TNF) inhibitors have been 
implemented at department level in hospitals. The study was performed as a part of the 
project entitled “Evaluation of the reform in the reimbursements system for TNF-inhibitors”, 
commissioned by the Ministry of Health and Care services. This study focuses on the use of 
the national guidelines for TNF-inhibitors published in June 2007. Clinical guidelines are 
developed in order to assist both practitioners and patients to reach appropriate health care 
decisions.  
METHODS: In this study, two groups of specialists in rheumatology were confronted with 
different questions concerning the guidelines for TNF-inhibitors and the spreadsheet from 
“Legemiddelinnkjøpssamarbeidet” (LIS). 8 specialists in rheumatology were interviewed, 
while the questionnaire was answered by 32 other rheumatology specialists. All the 
interviewees were picked randomly, from different parts of the country. The questionnaires 
were sent to the remaining specialists in rheumatology working in Norway, with some 
exceptions.  
RESULTS: The analyses show that the majority of informants are positive to the clinical 
guidelines for TNF-inhibitors. The respondents seem to accept these guidelines as a 
framework in their clinical work day. The spreadsheet from LIS on the other hand, is 
considered less useful than the guidelines, most of all because they are perceived as too time-
consuming. However, the informants stressed that they use their clinical experiences which 
is within these recommendations.  
CONCLUSION: The results based on this analysis show that the implementation of the 
clinical guidelines for TNF-inhibitors has been successful. The guideline is considered well 
suited due to rheumatologists clinical work day and provide for more equal treatment in the 
entire country. The spreadsheet from LIS, on the other hand, turns out to be considered less 
useful.  
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Abbreviations and acronyms 
DAS DISEASE ACTIVITY SCORE 
DMARD DISEASE MODIFYING ANTI-RHEUMATIC DRUG 
GP GENERAL PRACTITIONER 
HF HEALTH ENTERPRISE 
LIS LEGEMIDDELINNKJØPSSAMARBEIDET (DRUG 
PROCUREMENT COOPERATION) 
MTX METHOTREXATE 
NOK NORWEGIAN KRONER 
NSAID NON-STEROIDAL ANTI-INFLAMMATORY DRUG 
PSA PSORIATIC ARTHRITIS 
RA RHEUMATOID ARTHRITIS  
RHF REGIONAL HEALTH ENTERPRISE  
TNF-ALFA 
INHIBITOR 
TUMOR NECROSIS FACTOR-ALFA INHIBITOR 
(TUMORNEKROSEFAKTOR HEMMERE) 
WHO WORLD HEALTH ORGANIZATION  
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1. Introduction 
Tumor Necrosis Factor-alpha (TNF) inhibitors and other biological inflammatory modifying 
pharmaceuticals1 are used in the treatment of rheumatic diseases, in addition to patients with 
skin- and intestinal diseases. The financing of these medicaments was partly transferred from 
the National Insurance Scheme (Folketrygden) to the health enterprises` (RHF) budgets from 
June 1 2006. Prior to June 2006 the National Insurance Scheme paid for treatment with 
TNF-inhibitors outside hospitals, while the hospitals paid for the out-patient treatment. After 
June 1 2006 the ministry proposed that all TNF- inhibitors should be financed over the 
health enterprises` budgets, due to statements saying that differences in the financing of 
TNF- inhibitors may affect clinician’s choice of medicament (St.prp. nr.1, 2005-2006). 
TNF-inhibitors are a collective term for several different medicaments which mainly replace 
each other. The pharmaceutical group given in hospitals consists of the medicaments 
Remicade, MabThera and Orencia, whereas Enbrel, Humira and Raptiva are home-
preparations. Among these, Enbrel and Remicade are the most used TNF-inhibitors, in fact, 
these were the most sold medicaments in 2008 (Apotekforeningen, 2009).  
This study is part of a project on the evaluation of the changed funding for TNF-inhibitors, 
and is on commission by the Ministry of Health and Care Services. The project was 
requested in order to find out how the new financing system for TNF-inhibitors works. 
Further, this study will take a closer look at the clinical guidelines for TNF-inhibitors which 
were introduced in June 2007. According to numbers from the Norwegian Prescription 
Database there seemed to be geographical differences in the use of TNF-inhibitors and 
therefore, the Ministry of Health and Care Services wanted to make national guidelines to 
secure quality and geographical similarity in use of TNF-inhibitors (St.prp. nr.1, 2005-2006). 
                                            
1 Further in this study, it will for simplicity be referred to as TNF- inhibitors 
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1.1 Background for the changed funding arrangement for 
TNF- inhibitors 
Treatment with TNF- inhibitors is costly, roughly 80 000-150 000 Norwegian kroner (NOK) 
per patient each year, and there has been a considerably increase in consumption. The former 
financing system gave few incentives in proportion to the right prioritizing because a great 
portion of the costs were covered by the arrangement of blue prescription 
(blåreseptordningen). The proposal of transferring the financing liability for TNF-inhibitors 
to the health enterprises is mainly equivalent to the financing arrangements in Denmark and 
Sweden (St.prp nr.1, 2005-2006).  
In some cases, medicaments will have a natural application both inside and outside hospitals, 
like the TNF-inhibitors Remicade and Enbrel (NOU 2003:1). Therefore, using Enbrel was 
free for the hospitals, whereas Remicade had to be paid for by the hospital. Thus, it was 
assumed that the hospitals could see in favor of prescribing Enbrel to patients to a greater 
extent than what it was medical motives for. Therefore, the Ministry of Health and Care 
Services decided that Enbrel no longer should be financed by the National Insurance 
Scheme; hence, it should be financed as Remicade was already financed. Hopefully, this 
would lead to a choice of Enbrel or Remicade made from purely medical considerations, and 
not based on differences in the funding basis (ibid, legemiddelgruppen TNF-hemmere, 
2006). There are great costs related to these medicaments, the most sold drugs in Norway in 
2008 was Enbrel, sold for 501, 9 million NOK. Further, Remicade was sold for 355, 8 
million NOK, which was an increase of respectively 12, 2 percent for Enbrel and 22, 4 
percent for Remicade, compared to 2007 (Apotekforeningen, 2009). Hence, it was therefore 
important to find a financing arrangement which does not affect the prescription of these 
medicaments.  
Having a National Insurance Scheme funding of medicaments outside the institution, 
involves third party financing, and thus weak price sensitivity (NOU 2003:1). Third party 
financing means that the one that pays for the medicament, in this case the National 
Insurance Scheme, is someone else than the one who decides the pharmaceutical use, which 
is the physician. The physician, on the other hand, is someone different than the user of the 
medicament, which is the patient. The individual physician who initiates the costs of 
medicines is therefore not faced with the costs of medicament use. However, when the 
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hospitals themselves finance their medicament use, they have a financial incentive to try to 
negotiate discounts on the purchase and select the cheapest among equivalent drugs (ibid).  
Before the financing arrangement, there were no existing price competitions between these 
medicaments, even if the medicaments are equivalent, because of the financing through the 
National Insurance Scheme and because of use of different reimbursement systems. The 
transfer of the financing responsibility would give equal financing arrangement for the 
medicaments, and hopefully that would stimulate to price competition (Legemiddelgruppen 
TNF- hemmere, 2006). Further, different financing arrangements between these 
medicaments may have lead to a choice of medicament which to a large extent was based on 
economic and not medical considerations; however, that is just a hypothesis.  
Previous studies show that the demand for health care services is dependent on what price 
the patients have to pay for the treatment. In several countries, Norway included, the 
Government subsidizes the price of the health care services. This means that the consumer 
does not have to pay the total cost for the treatment they demand. This will lead to higher 
demands of these services, which is too high when it leads to services where the benefit of 
health is not in a reasonable relation to the production costs. Because of missing price 
mechanism, this might happen, and it will lead to irrational resource use, seen from a socio-
economic point of view (NOU 2003:1).  
1.2 Evaluation of the changed funding for TNF- inhibitors 
By transferring the financing of all the medicaments to the health enterprises, this would 
adjust for price competition between the producers through 
“Legemiddelinnkjøpssamarbeidet”2 (Drug procurement cooperation) and justify for more 
accurate prioritizing (Legemiddelgruppen TNF-hemmere, 2006, St.prp nr. 1, 2005-2006). 
LIS is an organization owned by the regional health enterprises, which task is to create 
competitive tendering on the hospitals` pharmaceutical procurement. LIS negotiate the prices 
with the pharmaceutical wholesalers on behalf of the hospitals through competitive biddings 
for selected drugs (Apotekforeningen, 2009). In addition, LIS has made a spreadsheet the 
specialists in rheumatology can use in order to find out which medicament is the cheapest for 
                                            
2 Further in this study, it will for simplicity be referred to as LIS 
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each patient. A third element, the Ministry of Health and care Services introduced clinical 
guidelines for use of TNF- inhibitors, in order to support right use professionally and 
economically, and contribute to secure equal treatment of patients in the entire country.  
The project on the evaluation of the changed funding for TNF- inhibitors is tripartite, with 
the following problems to be addressed:  
- How has the changes in the financing responsibility affected the distribution and use 
of TNF- inhibitors? 
- How has the transfer of the financing responsibility affected the price competition in 
this area? 
- How are the national guidelines for TNF- inhibitors implemented at department level 
in hospitals?  
The last question is the problem that will be addressed in detail in this study. However, the 
two other studies might be of interest since they address the other aspects of this project. 
Hence, I refer the reader to the studies “An analysis of consumption and use of TNF-
inhibitors”, written by Silje Hobbel and “Price and competition in the market for TNF-α 
inhibitors in Norway”, written by Irina Bjarkum.   
1.3 National clinical guidelines 
According to Grimshaw & Russell (1993), clinical guidelines are statements which are 
systematically developed in order to assist practitioner’s decisions about appropriate health 
care for specific clinical circumstances. In these statements there is a thoroughfare of 
available knowledge in the special field. 
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1.3.1 Introduction of national guidelines for TNF- inhibitors 
 
The Norwegian Directorate of Health published the national professional guidelines for 
clinicians prescribing TNF-inhibitors in Norway: “National professional guidelines for the 
use of TNF- inhibitors and other biological inflammation calming medicaments within 
rheumatology, gastroenterology and dermatology”. Clinical practice guidelines are 
developed in order to improve health care outcomes and health service efficiency, and 
hopefully reduce levels of inappropriate practice (Grimshaw & Russell, 1993, Conroy & 
Shannon, 1995). In addition to the national guidelines, every hospital department is 
recommended by the guidelines work group to make procedures suitable for treatment with 
TNF- inhibitors in their hospital department. This is because the recommendations in the 
national guidelines neither are detailed nor complete (Retningslinjer for TNF-hemmere, 
2007). 
 
1.3.2 The aim of the national guidelines  
The aim of clinical guidelines is to gather sources of knowledge with a basis for education, 
in order to create a tool in practice for the clinicians. However, guidelines are also policy, 
which is meant to be a basis for quality evaluations and a basis for co-operation between 
disciplines. Further, guidelines can secure a good relationship between costs and utility and 
at last, work as a tool for rationing of services. Finally, the aim of the clinical guidelines 
shall secure high quality, secure right prioritizing and reduce unwanted variation (Carlsen, 
2008).  
The Ministry of Health and Care Services gave the Directorate of Health commission to 
work out national guidelines for use of biological inflammation calming medicaments. The 
Ministry of Health and Care Services requested for guidelines that should support right use 
of the medicaments both professionally and financially, and contribute to ensure equal 
treatment of patients in the entire country. By creating these guidelines, the Government 
wanted to make superior instructions for the particular professional environment based on 
today’s knowledge for the registered medicaments. The national guidelines are based on 
international reputable principles, for treating patients with seriously inflammatory 
rheumatic diseases (Henriksen, 2005).  
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1.3.3 Contens of the national guidelines for TNF-inhibitors 
The national professional guidelines for TNF-inhibitors are applicable within rheumatology, 
gastroenterology and dermatology, and were prepared by a composed group, set up by the 
Directorate of Health. The work group consisted of representatives from Norwegian 
Medicines Agency, Norwegian Knowledge Centre for the Health Services, the regional 
health enterprises and the Directorate of Health. In addition, “Norsk revmatologisk 
forening”, “Norsk dermatologisk forening” and “Norsk gastroenterologisk forening”; which 
are the Norwegian associations in rheumatology, dermatology and gastroenterology, 
participated in this work. The national guidelines for TNF-inhibitors are threefold, and 
discuss guidelines for respectively inflammatory rheumatic diseases, inflammatory intestinal 
disease and dermatological diseases. Further in this study, the national guidelines for the use 
of biological medicaments in inflammatory rheumatic diseases will be the focus.  
Mainly, each chapter in the guideline is divided into instructions according to prescription, 
which medicaments the recommendation relates to, treatment with biological drugs, current 
contra- indications of treatment, follow- up of patients under treatment and finally, the end of 
treatment. In the first subchapter, the guidelines examine prescription and prescription 
practices for TNF-inhibitors. Here it is described that biological medicaments have to be 
prescribed by specialists in rheumatology, further, the prescription have to be approved by 
the professional environment at a public or a non-commercial private hospital, with at least 
to specialists in rheumatology. Further, there is a short description of which medicaments the 
recommendation relates to and for which approved indications this applies, while other 
indications have to be approved at a university department. In the guidelines there is set 
different requirements for disease activity. The TNF-inhibitors are to be used in the 
treatment of patients with active inflammatory disease, which have not responded 
satisfactory on conventional treatment using Disease Modifying Anti-Rheumatic Drug 
(DMARDs), antiphlogistic medicaments or possibly intraarticular steroid injections. The 
evaluation of disease activity should be based on relevant parameters for inflammation like 
laboratory tests, clinical status and pictorial-diagnostics. The patients must have completed 
previous treatment and have to be without contra-indications in accordance with 
international approved literature at the start of the treatment and are to be checked regularly. 
These contra-indications are among others, infections, malignity, pregnancy and 
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contemporary treatment. Finally, all treatment has to be ended after 3-6 months if the patient 
has not achieved intended treatment response.  
1.4 Use of theory  
The theoretical framework in this study will handle the principal-agent theory, including 
different uncertainties and conflicts. According to Chambliss and Schutt (2006), theories 
help us make connections to general social processes and large bodies of research. 
1.4.1 The agency theory (principal-agent theory) 
Despite the fact that clinical guidelines are made to facilitate better practice, many 
practitioners are sceptical as to whether the clinical guidelines can improve their clinical 
work day. Hence, uncertainty persists concerning whether guidelines are effective or not 
(Grimshaw & Russell, 1993), and negative issues due to the introduction of guidelines are 
the same as those affecting any new health care development (Conroy and Shannon, 1995).  
In the principal-agent theory we analyze the relationship between a principal (P) and an 
agent (A). According to Busch and Vanebo (2003) an agent relation is:”A contract in which 
one or more persons (the principals) engage another person (the agent) to do a job for them 
and this implies that a certain way of decision-making authority is delegated to the agent” 
(Jensen and Meckling, 1976 in Busch and Vanebo, 2003, p. 118). Because of reliance on the 
agent, the agent has more information than the principal, and this might lead to asymmetry 
of information. Furthermore, the agent does not necessary have the same goals and/or 
objectives as the principal, and therefore this might lead to problems (Smith et al., 1997). In 
this case, the Government (P) is dependent upon the hospital and the employees’ (A) 
performance to be able to achieve the goals that are formulated; that is, implementation of 
the national guidelines for TNF-inhibitors.  
In this study, due to the implementation of clinical guidelines for TNF-inhibitors, some 
problems may arise. The principal and the agent might have conflicting goals, like different 
preferences. Additionally, there might be asymmetric information between the principal and 
the agent. 
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Based on the data from the interviews and the survey, there will be an analysis and 
discussion, taking a closer look at these data and then discussing the findings in this study. In 
the analysis there are made use of results from the survey and the interviews, first of all to 
show the reader some of the answers from the data collection. Among other factors, the 
questions deals with the respondents’ knowledge of and access to the clinical guidelines for 
TNF-inhibitors, where they got it, and whether they know the content of the guidelines. 
Further, they were questioned whether the guidelines are made use of in their clinical work 
day.  
1.4.2 Former studies 
In order to get a better understanding of the need for an evaluation of the new financing 
system for TNF-inhibitors, and the implementation of the clinical guidelines, it is of interest 
to take a look at former studies concerning clinical guidelines. In addition, the principal-
agent set of problems and earlier composed reports on the use of biological inflammation 
calming medicaments within rheumatology, will be briefly discussed.  
The Norwegian Knowledge Centre for the Health Services has made a study where they 
investigated the economic aspects of TNF-inhibitors in Norway. Their results reported that 
TNF-inhibitors can be cost effective, compared to treatment with DMARDs. This was 
especially the case where it was used in early stages of the disease; less than three years, and 
by patients witch, among others, had a good DAS 28 response (DAS 28 indicates the disease 
score). Further, they found that prevention of productivity loss might lead to great potential 
savings for the society; however, this was only discussed in a few of the economic 
evaluations done (Movik, 1997). 
According to the article "What lies beneath it all? – an interview study of GPs' (general 
practitioners) attitudes to the use of guidelines”, GP`s adopt clinical practice guidelines to 
varying degrees (Carlsen & Nordheim, 2008). Here, it is stated that GPs attitudes towards 
guidelines identified common barriers to implementation, and these barriers are similar 
across studies and countries (ibid). There might be different reasons for this; however, 
whether the guidelines are trustworthy, whether they suit the patients and whether the 
recommended action is feasible, are important considerations for the GP. Further, there were 
two important findings, according to the paper. First of all, the GP`s suspects that clinical 
guidelines from the Government are strongly affected by financial considerations. Second, in 
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contrast to earlier findings, the article have come to the result saying that even if some 
clinicians indicate that recommendations at times might seem confusing, they still think it is 
of importance to have a debate about, and updates of, clinical guidelines. This is other results 
than similar studies have shown in other countries, however, an explanation might be that 
there are a relatively small number of guidelines in Norway, which means less to keep track 
of.  On the other hand, it is possible that evidence based medicine and transparent academic 
debate has become more accepted the last couple of years (Carlsen & Nordheim, 2008).  
1.5 Use of method and the task ahead 
1.5.1 Use of method 
In this study it is both made use of qualitative-and quantitative methodology. By making a 
survey we reached out to several rheumatologists, and therefore got several views on the 
guidelines for TNF-inhibitors, while using qualitative method, we got more detailed 
answers, based on the interviewees’ experiences, thoughts, expectations and attitudes 
towards the guidelines.   
Further, the interviews will serve as data base, while the survey is intended as a supplement. 
It was conducted six interviews with clinicians from four different hospitals in Norway, in 
addition to one private clinic. The first two interviews were carried out with two 
interviewees in each interview; hence, the last six interviews were conducted with one 
interviewee. While one of the interviews was a telephone interview, the others took place at 
the hospitals and the clinic. The survey was sent out to a great number of rheumatologists in 
Norway; however, the response rate was only 32 percent. Thus, the interviews were chosen 
to be the main source of data, while the survey was included as a supplement, which 
captured knowledge about the guidelines more widely.  
The study further, beyond what has already been mentioned, will examine the 
pharmaceutical market and the overall pharmaceutical policy objectives in addition to a short 
description of the rheumatic diseases and treatment. Chapter 2 is included in order to provide 
a better understanding of the mechanisms in the pharmaceutical market, while chapter 3 is 
intended to provide an understanding of why it was important to implement clinical 
guidelines in relation to the use of TNF-inhibitors for these diseases. Further, there will be an 
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analysis and discussion in chapter 6. In the analysis of the data from the interviewees there 
has been made use of statements, which will hopefully give the reader an impression of the 
interaction during the interviews. Hopefully, this will exemplify the material, which forms 
the basis for the analysis. Further, the survey results will hopefully give an impression of the 
response rate and then what results was found based on the data collection. Finally, in 
chapter 7 there will be concluding remarks, discussing the findings and summing up this 
study.   
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2. The pharmaceutical market and overall 
pharmaceutical policy objectives  
This chapter will examine some of the pharmaceutical sales, market conditions and the 
participants involved in the pharmaceutical market. These are challenges, which have to be 
resolved in order to achieve a best possible use of pharmaceuticals. Hopefully, this will 
provide a better understanding of why the government wants to introduce guidelines for the 
use of certain medications, in this case the TNF-inhibitors.  
Pharmaceuticals are partly financed by the Government through the arrangement of blue 
prescription, partly by the regional health authorities, partly by other health institutions, and 
partly by patients through out-of-pocket payment for blue prescriptions, white prescriptions 
and nonprescription pharmaceuticals. For some pharmaceuticals, the regional health 
authorities have a distinct financing responsibility. This is applicable for disease modifying 
biological medicaments for treatment of rheumatic diseases, the so-called TNF-inhibitors 
(Apotekforeningen, 2009). In 2008, there were sold medicaments for 17, 1 billions in 
Norway, which was an increase in 2, 9 percent compared to 2007. The sale was divided 
between marketed prescription required medication, prescribed drugs given authorization 
exemption (godkjenningsfritak) and nonprescription drugs. According to the ATC-
classification, which is an international classification system for pharmaceuticals 
recommended by the World Health Organization (WHO); the ATC-group consisting of 
antineoplastic and immunmodulating agents increased 11 percent from 2007. This group is 
mainly dominated by pharmaceuticals for arthritis and similar and for cancer treatment. The 
high increase is related to the fact that there has been a large increase in the sale of the TNF-
inhibitors Enbrel, Remicade and Humira (ibid).  
2.1 The participants in the pharmaceutical market in Norway 
The pharmaceutical market is a market, which is different from other markets; hence, it is a 
strictly regulated market. There are different strong and dominating participants in the 
market, at the same time as there are great economic interests from the different participants. 
The most central participants on the pharmaceutical market in Norway are the public 
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authorities, the pharmaceutical industry, the pharmaceutical wholesalers, the pharmacies, the 
patients and the health personnel (Apotekforeningen, 2008, St.meld. nr. 18, 2004-2005).  
2.1.1 The public authorities 
The public authorities, represented by the Ministry of Health and Care Services, are 
responsible for the administration of the pharmaceutical politics. This includes regulation by 
law and financing of the pharmaceuticals over the National Insurance Scheme. In addition, 
other tasks are delegated to underlying departments. The Norwegian Medicines Agency 
ensures the consumers and health services` needs for effective and secure medicaments, and 
also contributes to accurate medicament use. Further, the agency is responsible for approval 
of medicaments` quality, safety and effect, admission of medicaments on the arrangement of 
blue prescription, pricing and supervision of the medicaments. Finally, the agency also 
supervises production, testing, distribution, sale and marketing of different medicaments. 
The Norwegian Directorate of Health is responsible for coordination of development and 
implementing professional guidelines at national level. Medicaments are one of several 
treatment alternatives that have to be evaluated. Further, the Directorate is responsible for 
the regulations of requisition and handling medicaments in the health service, and finally, 
preparedness. The Norwegian Institute of Public Health is a national centre, which is doing 
research, health supervision and counseling within infectious disease control, environmental 
medicine and demographic surveys. The Institute also has the responsibility for vaccination; 
among others, the Norwegian Prescription Database (Reseptbasert legemiddelregister). 
Hence, the National Insurance Scheme administers the arrangement of contribution and 
individual reimbursement for medicaments, keeps control with the prescriptions written on 
the National Insurance Schemes account, and stands for the refund settlements with the 
pharmacies. Finally, the Norwegian Board of Health Supervision is responsible for the 
supervision of the health care services and medical personnel; including clinicians` 
prescription of medicaments and handling of medications in institutions (Dalen, 2003, 
St.meld. nr. 18, 2004-2005). 
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2.1.2  The pharmaceutical industry, pharmaceutical  wholesalers 
and the pharmacies 
First, the pharmaceutical industry develops, produce and sell medicaments, and there are 
made considerable demands for safety, quality control and follow-ups in these stages. Today 
there are more than 40 different pharmaceutical agencies in the Norwegian market and about 
300 pharmaceutical companies with marketing permission in this market (St.meld. nr. 18, 
2004-2005). Second, the pharmaceutical wholesalers buy medicaments from the 
pharmaceutical companies and resell them to the pharmacies. There are three full assortment 
wholesalers in Norway: Norsk Medisinaldepot, Tamro and Holtung (ibid). Third, the 
pharmacies process the medicaments to the patient prescribed by a physician, and have to 
distribute all medicaments that are demanded by the patients. The pharmacies incidentally 
buy all medicaments and most of the other products from the pharmaceutical wholesalers 
(ibid).  
2.1.3 Patients and health personnel  
Patients can improve their knowledge and understanding about the use of medicaments by 
gathering information, due to today’s technology, which makes it simpler for the patient to 
obtain this information. Patients with chronic diseases often gather a lot of information about 
their health condition and their treatment possibilities (St.meld. nr. 18, 2004-2005).  
The relationship between the patient and the clinician used to be characterized by more 
confidence and accept than what is the case today. Now the patient’ have a more 
participating role, due to more knowledge about own health and about the health care 
services. There has been a change as a result of co-operation, co-determination and joint 
responsibility. Further, the treatment of many diseases has become more complicated with 
more and more medicaments and a number of advanced types of treatment. In different 
cases, it requires many years of experience and high skills in order to give patients the right 
information and good advice about treatment and medicaments. Hence, it is important that 
the clinician does not act contrary to health personnel's duty of providing good care and 
economically correct use. Research shows that patients have significant influence over what 
happens during the consultation, due to the fact that they have become more informed and 
often know a lot about different treatments and medicaments. Hence, it is important that the 
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treatments and the medicaments are used as they are supposed to, both professionally and 
financially. Appropriate pharmaceutical use is the ministry's primary objective of 
pharmaceutical policy, thus it is important to have a good prescription culture and patient 
follow-ups to ensure right use of medicaments (St.meld. nr. 18, 2004-2005).  
In total, 70 % of the pharmaceutical costs are paid by the National Insurance Scheme, while 
the patients cover the rest through out-of-pocket payment, and payment for white 
prescriptions and nonprescription drugs. The reimbursement arrangement for 
pharmaceuticals is part of the Governments management tool within health-and welfare 
policy, and is established with two different purposes. First of all, it is established to ensure 
that the whole population has access to necessary medicaments, independent of their ability 
to pay. Secondly, the arrangement will help to ensure correct and cost-effective use of 
medicaments (St.meld. nr. 18:2004-2005).   
As mentioned, there are great costs related to medicaments in Norway every year. Every 
year there is great demand for health services in Norway, and the demand only increases. 
Rheumatic diseases is one of the major disease groups in Norway, around 300 000 have a 
rheumatic disease (Revmatikerguiden, 28.04.09). This will be discussed further in this study.  
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3. Rheumatic diseases and treatment  
Since rheumatic diseases are common in Norway and attended with great costs, it is 
important to have a framework for treatment of such diseases. The guidelines for TNF-
inhibitors have requirements for how the worst cases of these diseases should be treated, and 
therefore, the last part of this chapter discusses treatment of rheumatic diseases in order to 
provide a better understanding of the importance of requirements due to such treatment.  
3.1 The rheumatic diseases 
Rheumatic disease is an umbrella term for more than 80 diseases that affects the moving 
body, additionally; internal organs may in some cases be affected as well. Inflammatory joint 
diseases are serious, and in total, nearly 300 000 Norwegians are expected to have a kind of 
rheumatic disease. In most cases, the causes of rheumatic diseases are unknown. Still, 
inheritance, environment and mode of living are important factors for the development of 
these diseases. However, common for the diseases under this term, is that our own immune 
response of unknown cause attacks the body’s own tissues and organs. What difficulties the 
diseases provide, both partly depends on which tissues and organs are attacked, and partly on 
how active and aggressive the disease is (Revmatikerguiden, 20.01.09). 
 
Fig. 1: Joint affected by rheumatoid arthritis (1) 
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3.1.1 Rheumatoid arthritis (RA)  
According to McRae & Kinninmonth (1997), Rheumatoid arthritis is a chronic, systemic 
inflammatory disorder of unknown aetiology. Rheumatoid arthritis is characterized by 
inflammation in joints, and for most people the disease first affects hands and feet, with 
symptoms like stiffness, soreness and pain. The inflammatory process is often recurrent, and 
this often leads to progressive joint destruction, deformity and incapacity. 
According to Revmatikerguiden (20.01.09), a webpage with information about rheumatic 
diseases, between 0, 5 and 2, 0 percent of the Norwegian population has Rheumatoid 
arthritis in Norway. The disease is more common among women, with a peak onset between 
the ages 50 and 60; however, both young and elder might get the disease. It is unknown what 
the cause of this effect is, but there are several factors that contribute to the disease. Since 
more women get the disease we can assume that it has to do with female hormones, 
additionally, heritability does also affect the chance of developing the disease. RA develops 
over several years, with constantly reduced mobility. The reduced movement due to the joint 
cartilage is gradually broken down and replaced by connective tissue fibers that get smaller. 
In the most extreme cases the binding tissue is destroyed, and all movement in the joint ends, 
however, it is only in 10 percent of the cases the disease leads to complete disability (Bjålie 
et.al, 2000).  
3.1.2 Bechterew’s- disease   
Bechterew’s-disease or Ankylosing Spondylitis, is a disease grouped under the Seronegative 
Spondyloarthropathies. Bechterew’s-disease is a chronic inflammatory arthritis, which 
injures the articulars between spine (columna) and the sacroilium (ileum). Further, the small 
articulars in the back develop inflammation, and in some cases other organs like eyes, heart 
and kidney might be affected. The cause of Bechterew’s-disease is not known, however, it is 
well known that the disease brakes out at a young age; often before turned 45. Getting the 
disease after turning 45- 50 years is unusual, and we see that males are affected more often 
than women. According to Revmatikerguiden, between 0, 6 and 1, 8 percent of the 
population in Norway has Bechterew’s- disease. The disease occurs more often in areas were 
the disease predisposing heredity factor (sykdomsdisponerende arvelighetsfaktor) HLA-B27 
is frequent, like in North-Norway and among the Sami people (Revmatikerguiden, 09.02.09).  
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3.1.3 Psoriatic arthritis (PsA) 
Psoriatic arthritis is a chronic inflammatory disease, caused by inflammation of the skin 
(psoriasis) and joints (arthritis). There is a relation between psoriasis and arthritis: 7 percent 
of those suffering from psoriasis will develop arthritis (McRae & Kinninmonth, 1997). The 
prevalence of Psoriasis arthritis is expected to be 0, 1 percent; in other words, 1 in 1000 
Norwegians is expected to have PsA, however, this is just estimation. Most common for 
Psoriatic arthritis, is that the patient gets the skin disease first and thereafter the arthritis. 
This turns out in nearly 75 percent of the cases, however, both diseases might develop at 
almost the same time, or the arthritis might develop first. People in all age groups can be 
affected; however, it is rare that children are affected by PsA. In most cases one can see that 
PsA starts in the age group 20-40 years, and women and men are affected equally 
(Revmatikerguiden, 09.02.09).   
3.2 Treatment of rheumatic diseases 
In cases with inflammatory articular diseases, the pharmaceuticals play an important role in 
the treatment. By using different medicaments one can reduce the pain or prevent 
inflammation in the affected joints. The medicaments make sure that the joints and muscles 
still functions by preventing inflammation. Often, patients with inflammatory articular 
diseases have to try different medicaments to find a proper treatment. It is not unusual to 
combine different medicaments to achieve the best possible treatment, however, what 
medicaments to use depends, among other factors, on what kind of disease there is, how 
serious the clinical picture is and the general health of the patient (Revmatikerguiden, 
30.03.09). This study mainly concentrates on medicaments with more long-term and 
vigorous effect against the inflammation, with focus on the biological medicaments. These 
are medicaments that are specifically aimed at one particular molecule which plays an 
important role in the inflammation process in the joints.  
3.2.1 Treatment with biological medicaments  
Treatment with DMARDs or other conventional treatment might reduce or delay the 
development of functional loss, and irreversible damages caused by the disease. Patients 
with either Rheumatoid arthritis or Psoriasis arthritis, should have tried at least one disease 
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modifying medicament; preferably Methotrexate. When it comes to Bechterew’s-disease, the 
patient must have tried at least two different NSAIDs (Non-Steroidal Anti- Inflammatory 
Drug) (Retningslinjer for TNF-hemmere, 2007). However, there are many examples where 
patients experience that these medicaments do not have any effect, particularly after long 
time usage. Treatment with TNF-inhibitors is an alternative for these patients. Based on 
knowledge about the prevalence, and the diseases degree of seriousness, today there are 
merely between 8000 and 9000 patients with inflammatory rheumatic diseases in Norway 
per year, which might be topical for treatment with TNF-inhibitors (Granum et al. 2006). 
The treatment is not curing, and the joint elements will come back after ended treatment, 
thus, there is still great uncertainty associated with this type of treatment (ibid). Common for 
all TNF-inhibitors is that the patients should be followed up by a specialist. Most specialists 
are employed at a hospital or have a contract with a regional health enterprise 
(Legemiddelgruppen TNF- hemmere, 2006).  
TNF-inhibitors were adopted in Norway in 1999. The straining point is a molecule called 
TNF-α; the protein TNF-α is being blocked. Usually, inflation is a useful reaction in the 
body, because the body is activated to render harmless enemies, for instance infectious 
material. However, for patients with arthritis or other inflammatory diseases, the immune 
system does not work the way it is supposed to, and therefore the inflammatory reaction is 
directed against the body’s tissues (Revmatikerguiden, 01.05.09).  
The biological medicaments might either be given intravenous in an outpatients` clinic 
within a couple of hours or as an injection the patient takes at home. These biological 
medicaments can be divided into three groups: Antibodies against the inflammatory 
substance TNF-α, contact Substance (receptor); which inhibits the inflammation substance 
TNF-alpha, and preparation inflammatory drug, which inhibits IL-1 (interleukin-1) 
(Biologiske lægemidler, 2009). In the first group we find the medicaments Remicade, which 
is given as an infusion at a hospital, and Humira, which is given as an injection the patients 
can take at home. In the second group we find Enbrel, which also is given as an injection, 
taken by the patient, at home. The last group includes Kineret, which, as in the case for 
Humira and Enbrel, also is given as an injection the patients takes themselves (ibid).  
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3.2.2 Biological medications` effects and side-effects  
 
 
Fig. 2: a) The normal component mechanism and b) the biological medicaments way to neutralize the 
inflammatory mechanism (2)  
According to Revmatikerguiden, choice of medicament is taken by the clinician, based on 
knowledge of the different medicaments. The efficacies of biological medicaments are best 
documented in patients with prolonged and severe rheumatoid arthritis. Approximately 1/3 
of the patients have very good effects of these medicaments, 1/3 have moderate to good 
effects and 1/3 have little or no effects of the medicaments. When it comes to the group of 
RA patients, who could benefit from biological medicaments, it is likely to increase as 
experience with the substances increases (Biologiske lægemidler, 2009). TNF- inhibitors 
often provides significant reduction of pain, morning stiffness, tiredness and clinical disease 
activity; reduced number of swollen and sore joints (Revmatikerguiden, 19.03.09).  
There are elements of uncertainty when it comes to use of biological medicaments and side-
effects. Since biological medicaments only have been used for a few years, one does not 
know the long-run side-effects, and should therefore oversee for these side-effects. 
According to the guidelines for TNF-inhibitors, there is still some uncertainty in whether 
The normal component mechanism: The 
inflammation occurs when the immune 
system affects the body’s own cells. This 
happens when an inflammatory substance 
attach to a receiver at a cell’s surface, and 
thus activates the cell to create inflammation. 
 
Biological medicaments can attach to the 
inflammatory substance, such that the 
inflammatory substance can not attach to the 
recipient on the cell surface. This can be done 
by using drugs that are either antibodies 
(Remicade and Humira), or constitute a false 
receive drug (Enbrel).   
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treatment with TNF- inhibitors gives higher risk for cancer (Retningslinjer for TNF-
hemmere, 2007). In some studies, the data indicates that there is a possible higher risk of 
cancer, while in other large patient follow-ups this is not documented. It is therefore 
important to use the medicaments with precautionary measures (Biologiske lægemidler, 
2009).  
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4. Theoretical framework 
4.1 Agency theory (principal-agent theory) 
In the agency theory we analyze the relationship between a principal and an agent. 
According to Smith et al. (1997, p. 41), “the principal-agent relationship implies the 
existence of a contract (either explicit or implicit) under which one or more persons (the 
principals) engage another person or persons (as agents) to perform a service on their 
behalf”. In such a contract, the agent undertakes some of the decision-making authority, and 
because of the reliance on the agent, it is likely that information asymmetry will exist, due to 
the fact that the agent has more information than the principal. Further, the principal and 
agent may have different goals and/or objectives and their attitudes towards risk might as 
well be different (ibid).  
 
Fig. 3: The basic idea of agency theory (3) 
As we can see from the figure, the basic idea of agency theory is the relationship between a 
principal (P), and an agent (A). The agent is the one that performs on behalf of the principal, 
which is the one that hires the agent to act on its behalf.  If there are no conflicting interests 
between the principal and the agent, there is no problem; however, conflicts of interests 
might occur. Hence, as in this case, the principal might therefore be dependent on giving the 
agent appropriate incentives to assure that the agent will act as required. Since economic 
rewards are not applicable, monitoring can provide better information and basis for possible 
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sanctions if the agent does not accomplish the tasks as the principal requires (NOU 2003:1, 
Smith et al., 1997). In an owner-manager relationship the owner is the principal and the 
manager of the organization is the agent. Often in such relationships, the agent possesses 
skills and abilities that are needed in order to perform the tasks. The principal might lack 
these skills and abilities, might be less effective in performing the tasks compared to the 
agent, or might spend its time more productively on other tasks (Petersen, 1993). 
Appropriate principal-agent relations in the health care service might be 
Government/regional health enterprises, regional health enterprises/health enterprises 
(hospitals) and hospital management/hospital department (NOU 2003:1). In this study, the 
principal-agent relationship between the Government and the hospitals, with a focus on the 
specialists in rheumatology, is what is interesting to study. Whether the clinical guidelines 
for TNF-inhibitors are being used, is also to be examined. If the guidelines are being used, 
there are no problems due to this, however, if they are not being used, that might lead to both 
information asymmetry and conflicts of interest.  
4.1.1 Asymmetric information 
The main issue concerning the principal-agent relationship is asymmetric information, which 
means that one party possesses more information than the other party. In a principal-agent 
relationship the main focus is the essential information the agent holds and which the 
principal does not have available (Sando & Andersen, 2007). In cases where the principal 
can observe all the actions the agent performs, there is symmetric information. However, in 
many case the agent has information about its action which the principal cannot observe, 
while the outcome, on the other hand, usually is observable for both. Earlier, the 
Government assumed it had the same information concerning the hospitals` cost structure 
and patient composition as the hospitals` management and employees. Though, most often 
this is not the case. The management and the employees will have more information both 
concerning the possibility for cost reduction and other organization methods, and with regard 
to the prioritization decisions taken. Here we talk about information imbalance, challenges 
which occur in cases of asymmetric information (NOU 2003:1). In other words, the 
specialists observe their own action while the Government can not observe it. Therefore, the 
principal cannot be sure whether the agent acts in its best interest. The action of the agent 
will always be important to the principal, and therefore, an agent problem will always exist 
as long as one actor’s interests depend on the achievement of another part (Petersen, 1993).  
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In this case, asymmetric information means that it is difficult for the Government to evaluate 
the number of patients treated with TNF-inhibitors in the hospitals. The rheumatologists are 
expected to be willing to treat more patients than the Government requests. Further, it is 
difficult to see whether the agent behaves in the manner the principal wants, in terms of 
treating patients in accordance to what is required, with a view to the recommendations in 
the guidelines. Moreover, it is also difficult for the principal to see if the patients are treated 
equally regardless of where they live in the country. Without any methods of treating this 
problem there might be a twist away from the desired tasks, hence, introduction of clinical 
guidelines is a way to handle this problem. Hence, this study shows one way of handlings 
this problem.  
4.1.2 Conflict of interests 
Conflict of interests, on the other hand, might occur in cases where the agent has other goals 
than the principal. Here, the information the two parties possesses is not longer the issue, 
however, their contrast of interest is. The specialists in the hospital (A) treat patients on 
behalf of the Government (P); however, the specialists might have different goals, even 
though that is in conflict with the principals` requests. In this case, the Government delegates 
the treatment responsibility of rheumatic patients to the specialists; however, there are some 
uncertainties in terms of whether the agent works as preferred, and in a way that benefits the 
principal (Petersen, 1993). The principal and the agent might have different goal structure 
and different procedures. The agent might work toward own goals and act opportunistic. 
This is difficult for the principal to discover, and therefore insecurity arises between the two 
parts (Smith et al., 1997).  
With a view to the guidelines, one might question whether the guidelines for TNF-inhibitors 
are being followed, and whether the principal-agent problems exist here. Information 
inequality exists between the regulating authority, the Ministry of Health and Care Services, 
and the specialists; hence, the ministry’s challenge is therefore to find solutions on the 
conflict of interest in which encourage the hospitals` management and employees to act in 
accordance with the principal’s interests (NOU 2003:1). Such conflict of interest might 
consist of the specialists’ wishes in order to treat all patients in the need for the treatment 
while the Government wants to reduce the treatment.  
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4.1.3 Possible solutions for management-related problems 
Implementation of the clinical guidelines for TNF-inhibitors is the main-perspective in this 
study. As mentioned, in the agency theory management-related problems might occur, due to 
different incompatible goals and asymmetric information. Often the principal lack different 
skills in order to accomplish different tasks, hence, the agent is hired based on possessing 
these skills and abilities (Petersen, 1993). However, there might be conflicts between the 
principal and agent due to these tasks. The specialists in rheumatology have been delegated 
the decision making responsibility by the Government, in treatment of rheumatic patients 
with TNF-inhibitors. Whether the delegation leads to conflicts of interests, depends on 
whether the agent’s preferences differ from the principals (Sørensen, 2005).  
Since the Government does not have full information about the agent`s actions, there might 
be conflicts due to the implementation of the required tasks. Hence, it is important that the 
Government can put to use different instruments in order to make the agent accomplish these 
tasks as the Government prefer. Implementation of measures to ensure that the agent acts 
match the principal`s requirements, is the main issue here. Hence, first the principal-agent 
theory point out two different actions which might ensure that the agent does not make 
allowances for own interests in stead of the principal’s interests. The first action is 
monitoring, which can be carried out in two different ways. Ex post control is direct 
monitoring which is supposed to provide for “correct decisions”. Examples on this kind of 
monitoring might be active controls, however, such controls are often costly to accomplish. 
Implementation of clinical guidelines is another solution, which this study is an example of. 
The rheumatologists’ actions are here the independent variable, in other words, the reason 
why the Government wants to implement guidelines, to get more control of the prescription 
practice for the TNF-inhibitors This is done by the authorities in order to achieve what they 
want, as a prerequisite in order to make sure that the rheumatologists act as the Government 
wants, in cases where there might be conflicts of interests. In this case, the clinical guidelines 
are bipartite. One the one hand, the guidelines is meant to advice the rheumatologists in what 
the principal requests from the agent. On the other hand, the guidelines say more about the 
Government`s goals, for instance due to patient treatment. There might be a conflict of 
interests between the principal and the agent as a result of how many patients they should 
treat with TNF-inhibitors. Hence, the principal creates clinical guidelines in order to tell the 
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agent how the treatment progress ought to be. This is one way the principal can assure that 
the agent acts as supposed to, even though their requests disagree.    
Clinical guidelines are an increasingly familiar part of clinical practice, and by creating 
guidelines one creates instructions in detailed clinical treatment. Due to challenges in today’s 
health care systems; rising healthcare costs, increased demand for health, more expensive 
technologies and an aging population, clinical guidelines are seen as a tool in order to make 
health care more consistent and efficient. Furthermore, clinicians, policy makers and payers 
also see guidelines as a tool for closing the gap between what clinicians do and what 
scientific evidence supports (Woolf et al., 1999).  
How the agent will behave in relation to such management decisions differs. The agent 
might accept such decisions, however, in cases where the agent is forced to accept them, 
there might be protests. Further, the principal and the agent might have different goals; there 
might for instance be cases where the principal wants to save money, while the agent does 
not agree. In such cases, there are contrasts of interests between the two parts. However, 
there might be cases where the decisions are in line with what the agent wants, hence, the 
accomplishment will neither be affected by conflicts of interest nor asymmetric information.  
The other way of monitoring the agent, is ex ante-control. Here, the authorities establish 
institutional mechanisms, which secure control of the public administration (Sørensen, 
2005). “Fire alarms” is a way to carry out ex-ante control and might function as a 
management tool for the Government. Fire alarms are informed third parties in which alarm 
when public services fail its mission. Interest groups, like the Norwegian association in 
rheumatology, often have good information about how the situation is for specific groups, 
and can therefore give information about services in cases where it is revealed information 
about failures, or possible failures, to the Government. There are different arrangements, 
which are established in order to help individuals and interest groups with alarm activity, 
mainly by giving access. Examples of such arrangements are ombud schemes, like 
“Pasientombudet”, and statutory rights, like “Pasientrettighetsloven”. Such statutory rights 
give the population a legal basis to promote their case (ibid).  
Due to a successful implementation in this case, there are some expectations that have to be 
fulfilled. First of all, the specialists in rheumatology need to feel confidence above the 
Government, if not they will oppose the new changes. Further, if these changes lead to a lot 
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of extra work for the specialists, if it becomes time-consuming to make allowance for the 
guidelines, it will probably lead to resistance among the specialists. As in this case, more 
than half of the respondents in the survey and most of the interviewees do not use the 
spreadsheet from LIS, because they find them too time-consuming without being particular 
useful. Thud, due to the guidelines the Government has implemented some tools, which will 
hopefully ensure that the specialists use these guidelines. According to the respondents in the 
interviews and the survey, it was important that rheumatologists participated in the 
preparation of these guidelines. Hence, there will probably be a better acceptance of the 
guidelines among the specialists when it is done this way, compared with preparation of such 
guidelines without the influence of someone who knows their clinical work day. Further, the 
respondents believe that the guidelines are well adapted to their clinical work, which also is 
important to avoid resistance towards implementation of these guidelines. According to one 
of the interviewees, it is important to have a framework for these medicaments, and if many 
specialists share this view that may also be a reason why the guidelines are being used.  
 
 34 
5. Methods and data  
5.1 Choice of methodological approach 
In order to investigate what considerations specialists in rheumatology have on this topic, we 
wanted to make use of both qualitative- and quantitative methodology. This was decided in 
order to capture knowledge both widely and deeply. Why it is desirable to combine these 
two methods is because in qualitative method one uses the experiences, thoughts, 
expectations and beliefs as the basis for data analysis, while in quantitative method it is 
required a more overall view. By combining both these methods, I have tried to both get a 
general picture of what the rheumatologists thinks about the guidelines, and also tried to get 
some more detailed answers in the shape of interviews. An overarching goal for qualitative 
studies is to develop an understanding of a phenomenon, connected to individuals in their 
own social context. The aim is to get an insight into how people deal with their situation 
(Dalen, 2004). The qualitative research interview tries to comprehend the world from the 
perspective of the person being interviewed, get the understanding of people’s experiences, 
and reveal their experience of the topic discussed (Kvale, 1997). When it comes to 
quantitative methodology, the result we wanted to achieve was based on a larger number of 
specialists in rheumatology to see whether they shared the views of the interviewees. As 
distinct from qualitative method where we collect much data on a few cases, the aim in the 
quantitative part is to collect less data from many cases (Chambliss & Schutt, 2006).  
5.2 Ethical guidelines 
One of the main ethical issues in research is confidentiality, and most often the primary 
focus of ethical concern in survey and interviewing research. Confidentiality in research 
means that we do not publish personal data that might reveal the interview objects identity 
(Chambliss and Schutt, 2006).  
First of all, the principle implies that the researcher have to make the informant anonymous 
when the results from the research is presented. Furthermore, the principle implies that 
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others cannot have access to the data. It is important that the trust the informant shows the 
interviewer is based on the fact that the interviewer will not reveal the information (ibid). 
In a research projects, it is very important to have consent by the participants before the 
project is commenced (NESH, 1999 in Dalen, 2004). It is important that the informants have 
all the information they need before the interview, both in order to avoid misunderstandings, 
but also to go through with the interview process in an accurate way.  
In this case, my supervisor and I agreed to contact different specialists in rheumatology from 
different parts of the country to arrange the interviews. First of all, we sent out letters to 
some specialists, asking whether they wanted to participate in this project. The letter 
(appendix I) informed the participants about the project and gave information about the 
interviews with specialists within rheumatology, which hopefully would give us an insight in 
how the guidelines are being used, how well they function and how they possibly can be 
improved. In the letter we informed the specialists that both wards and individuals would be 
ensured fully anonymity both during the process and in the reporting of the results. Most of 
the specialists we contacted wanted to participate, and we set up a date. Some days before 
the interview took place I sent out the interview guide (appendix II), repeating some of the 
information from the letter concerning anonymity, and also information about use of 
supporting materials and the possibility to withdraw from the interview at any time during 
the process if that was required. The interviewees got a copy from the interview after the 
transcription and first analysis for acceptance and possible correction.  
5.3 Validity, reliability and generalization  
In both qualitative and quantitative research it is important to ensure validity, reliability and 
generalization. It is important that this is done through all steps in the research process; 
hence, one should ask whether the data collected are good enough to explain what they are 
intended to explain. The two main criteria’s for data quality is validity and reliability.  
5.3.1 Validity 
According to Chambliss & Schutt (2006) validity is “the state that exists when statements or 
conclusions about empirical reality are correct”. Do the indicators measure what it was 
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intended to measure? When we are trying to ensure whether the data is valid, aspects like 
truth and knowledge are important. A valid conclusion is based on precise terms and is 
connected with an assessment of the quality of the interpretations; therefore, it is important 
that the researcher is critical to his or her interpretations (Thagaard, 2003, Kvale, 1997). 
Whether we can ensure validity, depends on whether we weighed our measurement options, 
if we have carefully constructed our questions and observational procedures and whether we 
have selected sensibly from the available data indicators (Chambliss & Schutt, 2006).  
In this study, I assume I have asked the right questions, without asking leading questions that 
distracted the respondents. The questions asked gave me the answer to what I was looking 
into, further, after making the questions for the interviews and survey, I had some outsiders 
get a look at the questions, to make sure they were not misunderstanding or leading. Along 
the way, I have been critical to my interpretations of the interview- and survey results, and 
believe that my understanding is in line with what the respondents actually said.  
5.3.2 Reliability 
Reliability means that our measure is affected less by error, or chance variation than in cases 
where we do not have reliable data or measure. Reliability has to do with the consistency of 
the research findings. “We cannot really measure a phenomenon if the measure we are using 
gives inconsistent results” (Chambliss and Schutt, 2006). Reliability is a question we ask our 
selves about the accuracy and the quality control of the investigation, the presentation and 
the interpretation of the results. When it comes to the external reliability, this is about 
weather others can make an analysis with the same data. To ensure reliability, the researcher 
has to account for how the data has been developed during the process, which means that the 
researcher has to differentiate between the information received during the research, and the 
researchers own evaluation of the information (Thagaard, 2003).  
In this thesis I used a tape recorder, which is a more trustworthy source than taking notes 
during an interview. In cases were we take notes, the interviewer has to reconstruct 
statements and citations, which often might be interpreted incorrectly (Thagaard, 2003). 
Using a tape recorder also ensured that I did not miss out important information from any of 
the interviews. Though, since all my interviews were conducted in Norwegian, I had to make 
sure that all the translation was done carefully, to avoid misunderstandings and 
misinterpretations.  
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5.3.3 Generalization 
According to Chambliss and Schutt (2006), the generalization of a study is the extent to 
which it can inform us about persons, places, or events that were not directly studied. As 
mentioned earlier, in qualitative interview studies, we most often talk about quite small, 
suitable selections closely attached to the focus of an actual study. By using our theoretical 
starting point, we should consider whether what we have seen and heard, can be generalized. 
To what extent can the results be transferred to other groups than those that have been 
examined (Dalen 2004)? A question which is often asked about interview studies is whether 
the findings are possible to generalize. In our everyday life we make expectations about what 
will happen in other, similar situations or with similar persons (Kvale, 1997). According to 
Thagaard (2003), generalization is especially relevant when it comes to case studies, where 
the possibilities to generalize are incorporated in the research design.  
In this thesis, I would argue that the interviewees’ experiences with the guidelines of TNF-
inhibitors could be applicable in other studies of knowledge of the guidelines for TNF-
inhibitors. When it comes to my assumptions in this context, this can only be investigated by 
further research.  
5.4 Qualitative method – the interview 
5.4.1 Informants 
The sample was collected as follows: Together with my supervisor we decided that we 
would like to accomplish four interviews with specialists in rheumatology and also two 
interviews with private specialists in rheumatology. The informants were picked 
incidentally; however, we wanted to include specialists from different parts of the country. 
After deciding who we wanted to include, we sent out a letter asking whether they wanted to 
join this project. In addition to this we wanted to send out a questionnaire to other specialists 
in rheumatology.  
I ended up having five interviews with specialists in rheumatology and one interview with a 
private specialist in rheumatology. My first two interviews are from the same hospital with 
two interviewees in each interview. The rest of the interviews are from different hospitals 
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and with only one interviewee. The age of the interviewees range from 39 to 66 years, and 
both males and females were represented; three females and six males.  
Interview 1: Interview with two female specialists in rheumatology, working in a medium- 
sized hospital in Western Norway. 
Interview 2: Interview with two male specialists in rheumatology, working in a medium- 
sized hospital in Western Norway.  
Interview 3: Interview with one male specialist in rheumatology, working in a small hospital 
in Eastern Norway.  
Interview 4: Interview with one male specialist in rheumatology, working in a small hospital 
in Eastern Norway.  
Interview 5: Interview with one male specialist in rheumatology, working as a private 
specialist in Eastern Norway.  
Interview 6: Interview with one female specialist in rheumatology, working in a large 
hospital in North Norway. 
We hoped to accomplish focus group interviews, which is interviews with a number of 
specialists from the same ward at the same time. In that way we hoped to succeed in having 
a discussion considering the guidelines in a competent clinical environment. Unfortunately, 
this was difficult to arrange, therefore, most interviews were accomplished with one 
interviewee from each hospital/clinic.  
5.4.2 Interview and interview guide 
An interview is an exchange of viewpoints (Dalen, 2004). Further, it is a conversation with a 
structure and an aim. The goal is to capture descriptions of the informants work day to be 
able to interpret the meaning of the phenomenon that is described (Kvale, 1997). In this 
context, the researcher is an instrument who is responsible for the collection, understanding 
and interpretation of the answers that result from the interview (Dalland, 2000).  
In a research interview it is desirable for the researcher to illustrate the theme and the 
problems that are being addressed due to the actual project (Dalen, 2004). The main 
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advantages doing personal interviews is that we get a lot of information from the 
interviewees in addition to the fact that personal interviews often have a high response rate. 
In this thesis I chose a semi-structured interview, which is more focused towards a special 
theme that was chosen on beforehand.  
After sending out the letter with information about the project and an inquiry about whether 
they wanted to participate in this project, I contacted the requested. Most of the requested 
were positive to this project, and wanted to participate. I let the participants decide time and 
place, and in all cases except from one, I went to the hospital/clinic to accomplish the 
interviews in their own environment. Since I wanted to do interviews with specialists from 
the entire country, one of the interviews was conducted on the telephone, because of the long 
travel distance. However, the interview was conducted in the same way as the other 
interviews.  
The aim in qualitative studies is to get an insight into how people deal with their situation 
(Dalen, 2004). Therefore, conducting the interviews and data collection in a safe 
environment was important, hence, it was important to let the interviewees decide time and 
place for the interview. All the interviews lasted between twenty and forty minutes. In most 
cases, the interviews were initiated with some small talk, some of the interviewees wanted to 
hear more about the project this thesis is a part of. I brought up the questions, and asked if I 
could use a tape recorder to tape the interview. All the interviewees accepted it, and I got 
started with the questions. Some of the interviewees were very eloquent and spoke freely 
about the questions as I asked them, and sometimes before I even got to address the 
questions. Others, however, needed to think more about the questions I asked, and I had to 
ask some supplementary questions in order to get an answer to the specific question. In some 
cases, I followed the interview guide to the letter, while in other cases; it was more like a 
conversation where we touched into the questions as we spoke. The interview guide had the 
same questions for all the interviewees, except from some changes in the interview guide 
sent to the private specialist (See footnotes in appendix II).  
An interview guide is a plan we have made for the interview. In this case, the interview 
guide is quite structured; it was detailed put together with finished formulated questions. The 
interview guide and the situation for the interview have a lot to say for the finishing process 
and the analysis, according to Dalland (2000). The interview guide might be a sketch of what 
kind of topics that will be covered or it might be a detailed layout with the exact question 
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formulations (Kvale, 1997). In this case, the interview guide was fairly detailed with quite 
determined questions and order (ibid). The background for choosing such a detailed layout 
and question formulations was to make the interviews and the questions as equal as possible, 
to be able to compare the results from all the interviews in the analysis. Therefore we used 
an analysis method which categorized the answers from the interviews, rather than a 
narrative analysis form, where the interviewee is less determined. The interview guide was 
divided into seven parts, which included different questions about different aspects of TNF-
inhibitors. It was divided in order to structure the questions in a good way, hopefully to get a 
systematic basis for the interview. The interview guide included both open ended questions 
where the interviewees were asked to speak more freely, while other questions were more 
fixed, to get more specific answers. I should probably have made a pilot interview on 
beforehand, however, because of the limit of time that was not done. Yet, the questions in 
the interview guide were examined by a contact person in the Ministry of Health and Care 
Services, and after some changes, the interview guide was sent out to the interviewees.  
5.4.3 Transcription 
By transcription it means to prepare the interview material for analysis, which often means 
to transcribe from oral speech to written text (Kvale, 1997). The transcription is not only a 
simple technical process, but also a process of interpretation. The transcription form depends 
on how the transcription will be used. In some cases, the general impression of the 
interviewees point of view is the most important, and than we might rephrase and compress 
the opinions. In other cases, however, the transcriptions might work as psychological 
analysis, and should therefore be carried out carefully and in the literal form (ibid).  
The transcription was time consuming, as expected. I transcribed each interview shortly after 
each interview took place, to assure that I still remembered well what had been said. All the 
interviews were of such quality that I had no problems hearing what the interviewees said, 
except from the telephone interview. However, since I transcribed the interviews shortly 
after it took place, I remembered most of what had been said in the part of the interview that 
was of poor quality. In addition, I sent out the interviews to the informants within a week 
after the interview for comments and approval, and got some comments from the respondent 
from the telephone interview which helped me get the interview right. All the interviews 
were transcribed word by word, to make sure I did not miss any details and than loose 
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valuable information. This way of transcribing is very time consuming, however, I was sure 
I got all the details written down. The transcribing was done in Norwegian, to ensure I did 
not loose information due to translation and excluding dialect in this phase of the analysis.  
5.5 Quantative method – the survey 
According to Chambliss and Schutt (2006, p. 137), “survey research collects information 
from a sample of individuals through their responses to standardized questions”.  
In addition to the interviews we decided to do a survey. Surveys are often used, because they 
are versatile, possible to generalize and efficient, and can therefore be used for a variety of 
problems. Further, there are relatively low costs connected with a survey, and the fact that it 
is possible to distribute the survey out to a great number of respondents, is often important 
arguments for doing a survey. In this case, I used a questionnaire made in Questback, which 
is a web based examination program for creating surveys, and sent it out by e-mail to the 
respondents. By using surveys in addition to interviews, I hoped to reach out to a larger 
number of informants; to be able to base our analysis on several respondents’ answers. We 
made a descriptive survey which seeks to measure certain phenomena, at one point in time 
(cross-sectional) (ibid).    
5.5.1 Informants  
The total number of specialists in rheumatology in Norway is 201; however, this includes 
both employed, pensioners and clinicians that are not members of the Norwegian Medical 
Association (NMA). Since NMA helped us sending out the questionnaire to their members, 
the total number of reachable specialists, were 124. The questionnaire was sent out to all 
these 124 respondents; however, I received e-mails from ten rheumatologists which of 
different reasons could not participate in the survey. There were different reasons why they 
could not participate; some were absent from work, some had no longer the same e-mail 
address (delivery status notification (failure)) and one had not been working with TNF-
inhibitors in a couple of years, and therefore, did not feel that she could answer these 
questions.  Seven of these rheumatologists were women, while three of them were men. 
Three of them were from hospitals in the East, two from North and one from South. When it 
comes to the last four, we had no information about where in the country they came from. 
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Further, the questionnaire was sent to all the interviewees as well, because NMA sent out 
this invitation to their members for us, and thus we had no opportunity to remove these 
respondents. However, those who had already been interviewed were told to ignore the 
invitation. The total number of respondents were therefore 106. The respondents had one 
week answering the questionnaire, than we sent out three reminders within four more days, 
and the total number of replies we got were 34, which is a response rate of 32 percent. Due 
to the time limit, we decided to include the survey despite the low response rate, to base our 
findings on some more data than just the interviews. In this study, the results from the survey 
have been used to support the findings from the interviewees, to be able to see if we could 
find relations in the response due to sex, age or region. However, the low response rate has 
been taken into account during the analysis and discussion. Why the response rate is so low, 
can be discussed. There might have been too little information in the invitation to the survey, 
which did not give enough information to catch the respondent. Further, some of the 
respondents expressed that they regularly received invitations to various surveys by mail and 
e-mail, and therefore did not take the time to answer all these enquiries. There might be 
several different reasons concerning the low number of respondents in this survey, however, 
that will not be discussed further in this study.  
Fig. 4: Questback: age of the respondents in the survey.  
 
The age of the respondents in the survey varied from 40 to 69 years, and there was a little 
predominance of men answering this survey; 55, 9 percent men.  
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Fig. 5: Numbers from Questback: Counties the respondents practice in (due to rounding, the total 
percentage in this figure is 102)  
As we can see from the diagram, there are no respondents from the counties Hedmark, Sogn 
og Fjordane or Aust-Agder, which means that most counties are represented in this survey.  
The part called “annet” is a group that consists of respondents that did not give up name of 
the county they practice in, but answered “Sør-Øst”, “Oppland-Buskerud”, “Agder-fylkene”, 
while one respondent did not give an answer to this question.  
5.6 Sources of error  
5.6.1 Linguistics 
In this study, all the respondents spoke Norwegian; hence, the interviews were conducted 
and transcribed in Norwegian. In my analysis, statements from the interviews and survey is 
an important part, therefore, I have translated all the quotations into English. I have tried to 
translate it as carefully and correct as possible, however, I might have lost some details 
because of the translation.   
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5.6.2 Sources of error in qualitative data analysis 
In qualitative data analysis, text is the raw data to be analyzed, and transform analysis into 
findings; however, no formula exists for the transformation (Chambliss & Schutt, 2006). 
Some ethical issues may arise in quality data analysis, and therefore, there are some aspects 
to be aware of. First of all, it is important to make sure the research integrity and research 
have been though of. I believe my study has been conducted carefully, thoughtfully and 
correctly based on the data used in this analysis. I believe I have used the data in a way that 
will produce authentic and valid conclusions which is in line with the data material from the 
interviews and the survey. Further, according to Chambliss & Schutt (2006), there is an issue 
about the use and misuse of results. In my interview guide, the interviewees got information 
about the interview process, and were told they would receive a copy from the interview and 
the analysis that was made, for acceptance and possible correction. That way, the 
interviewees could comment on the first outline of the interviews, and control for possible 
errors in the transcription and. The interviewees were also told what the purpose of this 
interview was, in order to specify what I would use the results for.  
5.6.3 Sources of error in quantitative data analysis 
Using simple statistics, it is possible for the researcher to say something about social 
phenomenon, identify relationships among them and explore the reasons for these 
relationships, among others. By using a carefully constructed sample from the entire 
population, this might help us get a simple summation of different situations (Chambliss & 
Schutt, 2006).   
As in the case for qualitative analysis, here there is also important to be aware of the issue 
concerning use and misuse of the results. Before answering the questionnaire, the 
respondents got information about the purpose of this survey, in order to specify what I 
would use the results for. The respondents also got information about the survey being 
anonymous. Further, I have been cautious about using survey data to say anything about 
causal hypothesis. According to Chambliss & Schutt (2006), there is always a possibility that 
variables we did not control for, or was not even measured in the survey, may produce 
spurious results, and are therefore important to be aware of. In this case, I have thought 
about such possibilities, and been cautious about it in my discussion and conclusion.  
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6. Analysis and discussion 
The interviews with my interviewees will be the basis for my analysis and discussion in 
addition to the 32 respondents on the questionnaire we sent out. There are many different 
ways of interpret the data, and it is important to mention that this is solely my interpretation. 
In the analysis and the discussion I will use statements from the interviews and the 
questionnaires, hopefully to give the reader an impression of the interaction during the 
interview, and exemplify the material which forms the basis for the analysis (Kvale, 1997). 
The analysis is divided into subchapters, in order to follow the chapters of my interview 
guide. Hopefully, this will structure the questions in a way that makes it more orderly to the 
reader. 
6.1 Knowledge of the national guidelines 
The basis for this part of the project concerning evaluation of the changed funding for TNF- 
inhibitors is how the national guidelines for TNF-inhibitors are implemented at department 
levels in hospitals. To be able to investigate this problem we asked the interviewees and 
respondents in the survey whether they knew about the national guidelines for TNF- 
inhibitors. Both the interviewees and all the respondents of the questionnaire knew about 
these guidelines, however, there were some uncertainties due to which authority that have 
prepared these guidelines. Some knew that it was the Directorate of Health; however, all 
knew that it was worked out on commission by the Ministry of Health and Care Services. 
Among the survey respondents there were many different answers to this question, however, 
most of the respondents knew about some of the involved in the preparation of these 
guidelines, like the Norwegian association in rheumatology and Norwegian Knowledge 
Centre for Health Services.  
When it comes to who should work out such guidelines, all the interviewees agreed that the 
guidelines ought to be worked out at such level, as long as the professional environment in 
rheumatology has been involved in the preparation of these guidelines. According to several 
interviewees, these medicaments` nature and price make this a special task that requires a 
certain administrative level. Among the respondents of the survey, on the other hand, most 
of them agreed with the interviewees, 79, 4 percent thought it should be as it is today. 
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However, a little more than 20 percent thought the guidelines should be worked out at a 
lower administrative level, or by others.  
As I have understood it gradually, the specialists in rheumatology have (…) 
been very involved in the preparation of the guidelines. The Norwegian 
rheumatic association (…) has been very active in this work. Before the 
guidelines came, there was a meeting where rheumatologists in Norway 
were invited. This was an opportunity to express ourselves if we wanted to! 
It seemed that the one representing the Government was responsive and 
listened to what was said. (…) (Interview 1) 
Further, the interviewees were asked to give a short description of the national guidelines for 
TNF- inhibitors. All the interviewees agreed that it is important to have clinical guidelines, 
because of the fact that these medicaments are both expensive and of a special kind as well 
as it is important to have a tool that gives information about the use of these medicaments. In 
addition, these guidelines are based on international recognized principles, which make these 
policies strong academically based.  
It is an overall guide for specialists who tells about (…) international 
knowledge and how it is most favorable to use these medicaments. 
(Interview 5) 
When it comes to whether the guidelines have influence in practice, the interviewees seem to 
agree on this, however, some believe that they are not followed rigid by all specialists. The 
majority of he respondents agreed that the guidelines have influence, however, 8, 8 percent 
are more uncertain. According to Carlsen (2008), clinicians` attitudes towards guidelines 
differ, depending on whether the purpose is to limit the clinicians` activity or to encourage 
use of new or more treatment. The researcher found, in several cases, that the fear of 
destroying the relationship to a patient is an obstacle, in addition to the fear of not fulfilling 
their professional relationship. Some of the interviewees agreed that this might be the case; 
however, they think it is difficult to speak on a general basis. The guidelines are supposed to 
function as a criterion set that provide for equal treatment in the country, to ensure that it is 
not developed some practices where the clinicians prescribes these medications more often 
or more rarely than the guidelines recommend.  
Yes, they have great influence in practice; however, I do not believe that 
they are followed completely. (…) all treatment with TNF- inhibitors should 
start here (at the hospital), but that is not done. There are also other 
clinicians in the county that start treatment on rheumatic patients, and that 
is not right. We had wanted that the guidelines were followed, such that we 
had control over it, as rheumatologists. In our department, however, we 
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follow the guidelines, not completely rigid of course, but we follow them. 
(Interview 1) 
In the guidelines, there are made several demands that have to be fulfilled before TNF- 
inhibitors can be prescribed, among others demand for earlier treatment (Retningslinjer for 
TNF- hemmere, 2007). This is first of all because of the fact that these medicaments are very 
costly, and also because there is uncertainty associated with the use of these medicaments. 
Since there are some uncertainties related to side-effects using TNF-inhibitors, the guidelines 
requires that one is careful, and tries other kinds of treatment before TNF- inhibitors are 
made use of. The interviewees were asked whether they think these demands are attended to, 
generally. In most cases, the interviewees agreed that this is important to keep in mind. It is 
important to try one or more of the more common medicaments first, and once they see that 
this does not work or does not work well enough, they should start treatment with the 
biological medicaments.  
Yes, at our hospital we follow the rules, at least in 80-90 % (of the cases). 
The patients are different, and there are other considerations that have to be 
made; there are long travel distances and so, but I believe that in 90% we 
follow the guidelines. It has been a bit difficult, we know this is an expensive 
medication, however, we does not know whether we are on the right level, if 
our threshold for starting point is correct, and if we are lying where we are 
supposed to. We believe that we lie a bit under the average in Norway, but 
we have no numbers saying that. (Interview 4) 
I believe that is well ensured! There are not many requirements made, there 
are only a few. This work is probably done under great influence by the 
participating rheumatologists. They have, most probable, made account for 
our clinical work day, so that is not a problem. (Interview 3) 
6.2 Contents of the guidelines 
Further questions dealt with the contents of the guidelines. Here, the length of the guidelines, 
whether the layout were orderly, updated and well informed,  in terms of what patient groups 
they included, were discussed. According to Carlsen (2008), guidelines are practical when 
they are long enough, transparent, orderly, readily available (electronic), updated and finally, 
have patient information. First of all, the length of the guideline was discussed. All 
interviewees shared the same opinion about the guidelines being long enough, and the survey 
respondents also agreed on this. Further, the interviewees were asked a question about 
whether the guidelines are orderly. By that it means whether the guidelines are structured in 
 48 
a well arranged way, which makes it easy-to-read. As in the previous question, all the 
interviewees agreed that the guidelines are orderly, and most of the respondents agreed on 
this.     
They are orderly! They are as orderly as they can be. Clinicians always 
have a primary need for a certain amount of freedom, and there might be 
times were we are on the boundaries in relation to the criteria’s… 
(Interview 2)  
The next question was about whether the guidelines are updated. In the national guidelines 
for TNF-inhibitors it is stated that there will be an annual audit of the recommendations; 
hence, we questioned whether this has been taken into consideration. The interviewees seem 
to think that there is no need to update these guidelines yearly; however, the respondents of 
the questionnaire were more divided in their opinions.  
 
Fig. 6: Questback: are the guidelines updated? 
As we can see from the graph, most of the respondents think the guidelines are updated, 
though, one third of the respondents do not think they are, due to the recommendation in the 
guideline.  
No! It was published in June 2007, and it is said that they should be updated 
annually, but as far as I know that has not been done. However, I do not 
believe that there have been any great changes in the international view on 
the use of it, (…). (Interview 5) 
Yes! There is no rapid development in rheumatology; therefore, these 
guidelines will probably last for many years. (Interview 3) 
N* 34 
 
1 Ja 
2 Nei 
3 Vet ikke 
 
*N = antall respondenter som har besvart 
spørsmålet 
 
 49 
The final question concerning the contents of the guidelines, looked at whether the 
guidelines in their opinion inform well about the patient group they include. The majority of 
the interviewees agreed that the guidelines have enough information about this; however, 
some believed it was slightly deficient.  
The results from the survey show that 89 percent think the guidelines inform well about the 
patient groups, however, 11 percent disagree with this. 
Yes! At least when it comes to arthritis and Psoriasis arthritis, I think they 
do. There may be difficulties in cases with Bechterew’s-disease, where we in 
an early stage do not manage to place diagnostic criteria’s, which might be 
quite out-of-date. We meet patients were we with 95% certainty can see that 
this is going to be a serious Bechterew’s-disease, and can see that they have 
symptomatology even if it has not been any alterations yet.(…) If we do not 
take this seriously, we are doing a bad job! Here, I think the guidelines are 
not totally waterproof, but I expect that there will be updates on this. 
(Interview 2) 
Yes, clearly! (Interview 5) 
6.3 Use of the guidelines 
When it comes to the questions about the use of the guidelines, there are more uncertainties. 
The first question is about the accessibility of the guidelines. Majority of the respondents 
believe that the guidelines are accessible; however, there is great uncertainty when it come to 
where they got the guidelines from the first time. 
 
 Fig. 7: Numbers from Questback: Where did you get the guidelines from the first time? 
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Those who answered “other” specified that they either got them from the Norwegian 
association in rheumatology, from their employer, a colleague or after participating in the 
preparation of the guidelines.   
Where did we get it? I have read it, but were did we get it? I should be able to find 
them within a few minutes on the internet, but actually, I have not tried. On the 
associations` web page most probably… I guess we can find it there, although I 
have not tried! (Interview 2) 
It is on the Directorate of Health’s web pages, and is easy to find! (Interview 5) 
When asking the question about practical importance, all the clinicians asked seemed to 
agree that it is important to have such guidelines as a reference work and something to relate 
to in their daily work. Some said that they are of great importance, while others think they 
are of moderate importance.  
 Fig. 8: Questback: practical importance of the guidelines 
 
As we can see from the figure on the question about the guidelines` practical importance, 61, 
8 percent said the guidelines are of great importance in their daily work.  
It is good to have a framework for the practice of these medicaments, because it is 
an enormous expectation in the society. Many patients believe that this is a 
miracle medicine, and we live under a pressure of letting patients try it, which 
earlier was difficult. (…) I believe that it is important for us clinicians to have 
such a restriction, telling us what we can do and what we can not do. I am 
breaking the law if I go beyond what is given in the guidelines. It is very good to 
have a framework like this; it is necessary, completely necessary! (…) (Interview 
2) 
These are medications which have  side effects, might have side effects, and which 
takes a good share of the healthcare budget, so the use should be fairly well 
regulated. It is very good that we have such a framework to act in accordance 
with. (Interview 4) 
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In the national guidelines for TNF-inhibitors, it is stated that every hospital department is 
recommended to establish their own arrangements for treatment with TNF-inhibitors, in 
addition to the guidelines. The reason for this is because the guidelines are neither detailed 
nor complete, and therefore it will obtain a greater degree of quality assurance for the use of 
these medicaments. According to some of the interviewees, their departments have not 
established own arrangements, hence, the rheumatologists in the department often discuss in 
plenary whether a patient should receive such treatment or not, which in their opinion, 
functions as an arrangement in addition to the guidelines. In the case of the respondents of 
the survey, 50 percent said they have own arrangements in their hospital department, while 
50 percent does not have that kind of arrangement. Most of the rheumatologists that have 
other arrangements established in the hospital/clinic, stated that by having such arrangements 
in order to have best possible control over the patients, and by discussing their patients in 
plenary, the decisions are never based on only one specialist’s opinion.  
We have a procedure, and in that procedure it says that there should be a 
consensus with at least two chief physicians. Usually, we take it up on the 
morning meeting if there is a patient who should start with such treatment. 
Than we discuss it in plenary and it is written in the patient’s journal. The 
group of clinicians is the committee. (Interview 4) 
6.4 Prescription culture 
Under the topic prescription culture, the first question is about who can prescribe TNF- 
inhibitors in their department. According to the guidelines, biological medicaments have to 
be prescribed by specialists in rheumatology, and the prescription has to be approved by the 
professional environment at a public or non-commercial private hospital by at least two 
specialists in rheumatology. Decisions about the prescription should be based on written 
documentation of the patients case history, previously undergone treatment and current 
health state. In the survey, 38, 2 percent answered that there are only specialists in 
rheumatology that can prescribe it, while 45, 2 percent answered that all doctors (included 
assistant residents) can prescribe it in their department. 16, 6 percent answered others; in one 
department a dermatologists can also prescribe TNF-inhibitors, while in another department 
both dermatologists and gastroenterologists can prescribe it.  
That is just me! That is, I can prescribe it as follow-up. Until the amendment  
of the rules I could initiate it too, but now the initiation has to take place in 
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a rheumatic department at a hospital, because it have to be at  least two 
specialists that agrees on the correct indication. Than I have to refer the 
patient (to the hospital) with the forms I have filled out and the information 
I have on the patient. (Interview 5) 
All clinicians can prescribe it! I am aware that the guidelines says 
specialist; however, a specialist is always involved in the ordinance. We 
have therefore allowed for assistant residents, a clinician in 
education/specialization, to renew a prescription. (Interview 4) 
The guidelines require two specialists when deciding whether a patient should be put on 
these medicaments. All the clinicians that have been interviewed agree that this is important, 
because of the fact that clinicians might have a different view in which patients should have 
TNF-inhibitors. Some clinicians might be less restrictive in the prescription, while others 
might be too restrictive. Therefore, it is important that the clinicians agree in every case, and 
that each initiation is discussed.  
 
Fig. 9: Questback: Prescription of TNF-inhibitors 
As we can see, in most cases, this is fixed procedure, however, nearly 12 percent of the 
respondents answer that this is not a fixed procedure in their hospital department or clinic.  
Yes, we do… This is because we think it is important to do it this way. Often, 
two physicians have a different view, so it should be discussed. Most often, 
we are at least three, often four or five… To get a more nuanced view on the 
matter of every single patient and treatment, it should be done this way. It 
was probably a bit different in the beginning when we started to use this 
kind of medication. It was probably so-so, but gradually we got accustomed 
N* 34 
 
1 Ja 
2 Nei 
3 Vet ikke 
 
*N = antall respondenter som har besvart 
spørsmålet 
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to the rules and the regulations. Even if it sometimes becomes a bit messy, 
we do it! (Interview 3) 
Several of the clinicians argue that there are variations in the prescription culture between 
the regions. This might be based on the fact that the clinicians are different individuals, who 
have different views when it comes to what is the right starting point for each patient. 
However, some believe that the guidelines might have lead to less variation, but they still 
believe that there will be a difference in the prescription culture based on individual 
differences.  
 
Fig. 10: Questback: Variation in prescription culture between the regions?  
Yes! There are some regions that express that they have a lower threshold 
for giving TNF- inhibitors. Maybe there are individuals… Some 
rheumatologists! There might be patients they give TNF- inhibitors to, 
patients I had thought we should not give it to. That it is too early, or here 
we should try something else. Whether there are any regional differences or 
not, I do not know. I have the impression that there are regional 
differences… If one of the leading rheumatologists at the hospital believes 
in starting the treatment early, the assistant residents in this department will 
pick it up… That is my impression! I do not know if that is correct, but I (…) 
have that impression. (Interview 1) 
As a follow-up question, I asked the interviewees whether they thought this would affect the 
patient treatment.  
 Yes, it does! In relation to that I regard that as different professional point 
of views. I am more conservative than the eldest rheumatologist here. (…). 
And such differences there both are and should be… It is important to have 
different professional views! (Interview 1) 
N* 34 
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*N = antall respondenter som har besvart 
spørsmålet 
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In accordance with the guidelines, other treatment should be tested before TNF-inhibitors are 
prescribed. In cases of Rheumatoid arthritis and Psoriasis arthritis, the patient should have 
tried at least one disease modifying medicament (DMARD), preferably Methotrexate. In the 
case of Bechterew’s-disease, the patients should try at least two different NSAIDs before 
trying TNF-inhibitors. The interviewees stated that they all try Methotrexate first, but there 
are differences concerning how many DMARDs they try before initiating TNF-inhibitors. 
All respondents of the survey answered that they all try other treatment before TNF-
inhibitors are prescribed.  
Yes… Most patients have used or are using Methotrexate, at least in cases 
of Rheumatoid arthritis or Psoriasis arthritis. There, close to 100 % have 
tried Methotrexate. And there are also some (patients) that are using a 
combination, Methotrexate and another medicament. For some, there are 
side-effects using Methotrexate, they will then have Salazopyrin or Arava. 
All (the patients) have tried at least one, and some have been through two, 
three, up to five DMARDs. (Interview 4) 
Yes, we are always using Methotrexate before we start biological treatment, 
but we are not using anything else than Methotrexate alone. We are not 
trying triple treatment or something like that, because new studies from 
international rheumatology show that the results from such treatment versus 
using only one (DMARD), are poor. We are going from non-responding or 
poor responding of Methotrexate to biological treatment. A combination!  
(Interview 3) 
6.5 Progress in prescription 
Most likely, the prescription culture was somewhat different before 2006. Several of the 
interviewees claimed that more patients get this treatment now, though, they assume that this 
is not because of the financing arrangement. A couple of the interviewees, on the other hand, 
believe that there are fewer patients receiving these drugs now than before the financing 
arrangement. However, they state that this is just an impression they have, and not 
something they know. They believe that especially after the guidelines came, more clinicians 
have tightening in the usage of these medicaments in relation to the indication position. 
Others believe that the increase in usage primarily have to do with the fact that there are no 
longer just the sickest patients that get this treatment.  
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Fig. 11: Questback: Changed prescription practice after June 2006?  
I believe there are more (patients) that get it now, but I believe that is 
independent of the financing arrangement. There are not more of the new 
patients that get it (biological treatment), but because we have built up the 
number of patients that get TNF- inhibitors over time. They came in `99; 
that was when we started to use it. Then, it was used on the very stringent 
indications, on the most damaged patients, but now we also start on new 
patients. However, we have not come up on the level where we perhaps 
should be yet. (…) when it comes to general biological treatment, there is 
development all the time. That affects it, that to, I believe. When it came, we 
were very skeptical in relation to side-effects and complications, and the 
medicaments were reserved the sickest patients, but we are not that 
skeptical anymore, we start earlier now. (Interview 1)  
The ministry thought it was important to establish a financing arrangement as neutral as 
possible for the TNF-inhibitors. Before, the hospital had partly financed Remicade, while the 
other TNF-inhibitors were financed through the arrangement of blue prescription. The fact 
that this treatment is very expensive requires right prioritizing. The financing arrangement 
that was established had weak incentives in relation to right prioritizing because parts of the 
costs were covered by a third party (St.prp nr. 1, 2005-2006). We therefore wanted to ask 
our interviewees if there had been a change in the prescription practice today.  This question 
was not asked in the survey.  
(…) we were even more careful then, I think we were. Had consensus then, 
we were out quite early discussing who should get this (treatment). In the 
beginning I believe the individual physician started without discussing who 
should get it, but well before July 1 2007 we started discussing it. (Interview 
4) 
N* 34 
 
1 Flere 
2 Færre 
3 Ingen endring 
4 Vet ikke 
 
*N = antall respondenter som har 
besvart spørsmålet
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6.6 Economic considerations 
Further, we asked whether the hospitals` budgets are affecting the assignments of TNF- 
inhibitors; if they make economic considerations before prescribing TNF- inhibitors. Most of 
the interviewees answer that the hospitals` budgets does not have an influence on the 
prescription of these medicaments, the focus is on the patient. Some are not quite sure who is 
paying for it, but since they do not hear anything about it, that is not important. They say 
they are in no doubt when they decide initiating these medicaments, and thus the economic 
considerations are unimportant. However, several state that they think about the economy, at 
least in cases where different medical alternatives are evaluated equally. This question was 
neither asked in the survey.  
Yes, we think economic if different medical alternatives are evaluated 
equally, which also is prepared for in the LIS-agreement. We have no order 
of using less TNF, even if the budget is to low compared to the prognosis for 
use. (Interview 6) 
6.7 Spreadsheet from “Legemiddelinnkjøpssamarbeidet” (LIS) 
According to NOU 2003:1, comprehensive purchase cooperation between most hospitals in 
the country has developed. The central actor is “Legemiddelinnkjøpssamarbeidet” (LIS), 
which is in charge of competitive bidding of selected medications. The interviewees were 
asked whether they know about LIS and the spreadsheet they have made for prescription of 
TNF- inhibitors. Most of the interviewees were familiar with it, however, in most cases, the 
spreadsheet was not used in their daily work. Most of the respondents in the survey also 
answered that they know about this spreadsheet, however, 11, 8 percent reported that they do 
not know about it. The majority of the clinicians argue that they do not need the spreadsheet 
in their daily work, because they know about it, and keeps that in mind when they decide 
what medicament each patient should have. They state that the spreadsheet is there, it is 
available, if they in need it. Further, one clinician mentioned that the choice of medicament 
is given, whether or not they have to calculate the number of kilos to find out which 
medicament is the cheapest in every case. Several of the interviewees state that there are 
other considerations that have to be made, considerations that may be more important in 
their opinion, like cases where the patients have long travel distances. Further, travel costs, 
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absence from work, lost performance at work, transport and nursing are not included either, 
and that is perceived as a weakness in the LIS- recommendations.  
 
Fig. 12: Numbers from Questback: How often is the spreadsheet used in your daily work? 
As we can see from the figure, 26 percent use the spreadsheet often, however, as much as 44 
percent use it seldom. There is also a small group of the respondents, 8 percent, which does 
not know about this spreadsheet.  
We know they are there, we kind of keep it in the back of our heads, 
however, there are often many considerations to make in relation to other 
factors. (…) we do not use the spreadsheet, we do not enter the numbers, but 
we think about weight and travel distance, the things that are written there. 
We are using it in the practical work, but we do not bother to compute it. 
(Interview 1) 
As a follow-up question, I asked those who answered that they did not use the spreadsheet, 
whether this had to do with the spreadsheet being to time consuming. The answer to that was 
in most cases that it had to do with clinical experience and not bothering to do it. In most 
cases it was used, however, it was not used actively. These last questions were not asked in 
the survey.  
We use our clinical experience… That is within the LIS- recommendations, 
and then it must be okay! (Interview 3) 
Further, the interviewees were asked whether they would have used the spreadsheet if it was 
less time-consuming or easier to use. The answer to this was that they would not, simply 
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because they felt they did not need a spreadsheet to calculate the numerical values, they 
could just make mental calculation when needed.  
Travel expenses, absence from work one day, (…) loss of performance at 
work, transport and nursing, that is not included, and that is a weakness in 
these LIS-recommendations. (Interview 4) 
Finally, the interviewees were asked whether they had any comments on how the 
spreadsheet could have been simplified.  
No, not really! I know where I have saved them on my e- mail, so I know 
where to find them within a few seconds. (Interview 2)  
On the question that was about comments to any changes in the guidelines, some of the 
interviewees had some commentaries. First of all, this was about Bechterew’s-disease, and 
whether the diagnosis criteria’s may be changed. Some clinicians feel that in cases where all 
common sense dictates you should start treatment, but where they can not make a diagnosis, 
this should have been ensured formally. Further, some think that the guidelines should be 
updated yearly and in addition sent out again, since some assistant residents only have a 
copy of the guidelines. They believe that it would also be a reminder to use the guidelines 
actively in their clinical work day. Nevertheless, all things considered, the clinicians are 
satisfied with the guidelines the way they are. Furthermore, the respondents were asked 
whether the interviewees perceive the attitudes towards the guidelines in their hospital 
department. Generally, the specialists perceive the guidelines as well received, it is good to 
have a most similar practice as possible in the entire country.  
Finally, I asked whether the respondents had any comments concerning what was discussed 
above. Some of the answers to that was that it is very important to keep in mind that these 
medicaments are available for those who need it the most. Some are afraid that they might 
end up in a situation where they, because of economic considerations or other reasons, have 
to reduce the number of patients using these medicaments. However, it is also important that 
the patients do not get to much influence, and therefore, the use of these medicaments has to 
be followed closely by the control authority. In addition, we do not know whether there 
might be long-run side-effects, and therefore we have to pay attention to what is being done 
in this field.  
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7. Concluding remarks 
In this study, the main problem to be addressed has been whether the national guidelines for 
TNF-inhibitors have been implemented at department level in hospitals. Due to this problem, 
we have based our questions in the interview guide and the questionnaire on the respondent’s 
knowledge of the national guidelines, use of the guidelines, prescription culture, economic 
considerations and their knowledge of the spreadsheet from 
“Legemiddelinnkjøpssamarbeidet” (LIS). In addition to get an overview of today’s situation, 
we also wanted to find out whether there has been changes in the treatment regime the last 
couple of years, due to the transfer of the financing responsibility in June 2006. According to 
Conroy & Shannon (1995), clinical guidelines are made to facilitate better practice; however, 
many practitioners are sceptical as to whether the clinical guidelines can improve their 
clinical work day, hence, uncertainty persists concerning whether guidelines are effective or 
not (Grimshaw & Russell, 1993). With a view to the clinical guidelines for TNF-inhibitors, 
one might therefore question whether these guidelines are being followed and whether the 
principal-agent problems exist here.   
Based on the results of both the interviews and the survey, roughly speaking, we can see that 
the respondents in most questions share the same impressions; however, there are some 
exceptions. In the questions concerning the national guidelines for TNF-inhibitors, the 
respondents seem to agree that it is important to have such guidelines, both due to the 
importance of having a tool in practice, but also in order to provide for equal treatment in the 
entire country. The aim of the guidelines is also to secure high quality and right prioritizing, 
which, according to the respondents, is important for these kinds of medicaments. Most of 
the respondents, both in the survey and in the interviews, agree that the guidelines for TNF-
inhibitors seem to have influence among the rheumatologists, and all the respondents answer 
that the guidelines have medium or great importance in their daily work. As far as 
prescription culture variations are concerned, the respondents seem to believe that there are 
differences between the regions in this matter; however, some respondents seem to question 
whether this is because of actual differences between the regions, or if it is due to the fact 
that the rheumatologists are different. When it comes to the spreadsheet from LIS, on the 
other hand, the respondents seem to agree that the spreadsheet is less useful than the 
guidelines. According to the response rate from Questback, roughly 40 percent use the 
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spreadsheet often or fairly often, roughly 44 percent use it seldom, and roughly 16 percent 
does not use it or does not know about it. The interviewees agreed that this spreadsheet was 
too time-consuming, however, they pointed out that they know about it, and that they use 
their clinical experience which is within the LIS-recommendations. Others mention that they 
do not use the spreadsheet accurate; hence, they know what factors to take into 
consideration, like weight and travel distance. However, some specialists believe that other 
considerations are important as well, though, they are not included in the spreadsheet from 
LIS. Here are travel costs, absence from work, lost performance at work, transport and 
nursing mentioned.  
Due to the spreadsheet from LIS, I have tried to systematize the respondents from the survey 
and the interviewees, to see if there is a pattern in the use of the spreadsheet due to age, sex 
and county/region. First of all, it is important to mention that these patterns only are based 
on the answers from 34 respondents in the survey and eight interviewees. It is therefore 
difficult to draw any conclusions in this matter; however, it might give us an idea if it turns 
out to be differences due to age, sex or county/region. According to the survey, there seem to 
be a tendency that more women never or seldom use the spreadsheet from LIS, and more 
men than women use the spreadsheet fairly often or often. Further, there are only men that 
do not know about the spreadsheet from LIS.  The interviewees seem to follow nearly the 
same pattern. In other words, there seem to be a great number of specialists in rheumatology 
which does not use this spreadsheet from LIS, even if the majority of the respondents know 
about it, hence, age does not seem to be of importance; neither does county. 
There is disagreement in whether there has been an alteration as a result of the changed 
financing responsibility for TNF-inhibitors after June 2006, with a view to the number of 
patients receiving these medicaments. The respondents in the survey seem to disagree 
concerning whether there has been an increase or no change in the number of patients 
receiving TNF-inhibitors after 2006. Several of the interviewees claim that more patients get 
this treatment now, though, they assume that this is not because of the financing 
arrangement. However, some of the interviewees believe that there are fewer patients 
receiving these drugs now. After the implementation of the guidelines, some of the 
respondents believe that the clinicians might have limited the usage of these medicaments 
due to the indication position. Others believe that the increase in usage primarily have to do 
with the fact that there are no longer just the sickest patients that get this treatment.  
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With a view to the principal-agent theory, there has been little resistance due to 
implementation of clinical guidelines for TNF-inhibitors. The specialists seem to accept 
these guidelines as a framework in their clinical working-day. One reason why they seem to 
have been accepted might be because the rheumatic special field participated in the 
preparation of these guidelines. Among others, the Norwegian association in rheumatology 
participated in the preparation of these guidelines. The greatest benefit for patients and 
almost anyone in the health care, with a view to the clinical guidelines, is that it can improve 
health outcomes, and in addition it can make sure that the patient treatment for identical 
medical treatment is the same, independent of their hospital or location. By using clinical 
guidelines, it is more likely that the patients will be treated in the same manner regardless of 
where they live in the country or by whom they are treated (Woolf et al., 1999). Further, 
clinical guidelines offer potential benefits for healthcare professionals as well, among others, 
they can improve the quality of clinical decisions. In some cases clinicians might be 
uncertain about how to proceed; hence the guidelines can offer explicit recommendations. 
Guidelines might improve the consistency of care when clinicians are accustomed to 
outdated practices, and they can provide recommendations in which assure the practitioners 
about the appropriateness of such guidelines. To clinicians in hospitals, guidelines can work 
as a point of reference in practice. To achieve better healthcare services, the guidelines 
recommendations about tests, treatments and treatment goals contribute to comply with the 
best care practice (ibid). Finally, for healthcare systems that provide services, like the 
Government in this case, clinical guidelines may be effective in order to improve efficiency 
and optimizing value for money (ibid). Given the data we have, we conclude that the 
clinicians are positive due to the clinical guidelines for TNF-inhibitors. According to the 
respondents in the survey and the interviewees, these guidelines are well suited due to their 
working-day, and since rheumatologists have participated in the preparation of these 
guidelines, they are perceived legitimate. Several specialists state that they appreciate having 
guidelines, due to the increasing demand for these medicaments. By having the guidelines as 
a reference level, they believe it is easier to act in accordance to what is required.  
According to the data in this study, there are some weaknesses. First of all, the response rate 
in the survey was only 32 percent. The survey was sent out to 106 respondents, however, 
after three reminders; there were still only 34 respondents. Due to time limit, we therefore 
had to continue with fewer respondents than expected, hence, we got respondents from 
different counties in the entire country, and therefore, this will not make any weaknesses in 
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the data. Thus, these results might help us point out some important factors due to the 
problems addressed in this study, and than make it possible to draw some conclusions based 
on these data.  
As said by Woolf et al. (1999), clinical guidelines are an increasingly familiar part of clinical 
practice, and by creating guidelines one creates instructions in detailed clinical treatment. In 
England for instance, guidelines have existed for decades and in Finland, more than 700 
guidelines have been published by national and local bodies since 1989. Thus, guidelines 
seem to become more important in health care, and Norwegian clinicians will probably be 
obliged to follow a number of guidelines in the future. However, one might discuss whether 
it is good to have guidelines or not. If the guideline is considered as a tool which can 
improve health care, it is good to have guidelines, however, if one is not accustomed to 
dealing with guidelines, it is not necessarily a help in the clinical work day. Hence, this 
might therefore be a problem of current interest which might be interesting to investigate 
further.  
In that case, it might be interesting to take a closer look at implementation of guidelines 
among Norwegian clinicians, perhaps also within other special fields. Further, due to the 
patient perspective, there is uncertainty in whether the health enterprises provides for all the 
patients that need TNF-inhibitors. This question was only asked the interviewees, hence, it 
might be difficult to draw any conclusions based on these statements, but might work as a 
basis for further discussion. Further, most of the clinicians I interviewed do not think that the 
hospitals` budgets are affecting the assignment of TNF-inhibitors; hence, approximately all 
patients in need of TNF-inhibitors will get it. The interviewees stated that the focus is on the 
patient, and that they are quite certain when starting this treatment. However, a number of 
the interviewees fear that the Government will reduce the use of these medicaments, which 
will lead to a prioritizing between different patients. This might be interesting to take a 
further look at in a few years, to see if there has been a tightening-up due to these 
medicaments, or if the use of these medicaments has continued to increase.  
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Appendix I: Letter of information to informants (translated) 
Evaluation of new finance system for TNF- inhibitors 
The financing of TNF- inhibitors and some other medicaments that is being used in the 
treatment of rheumatologic diseases, was transferred from the National Insurance Scheme to 
the health enterprises` budget from June 1 2006. The transfer of the financing liability 
occurred at the same time as the introduction of national guidelines for consumption of TNF- 
inhibitors.  
It was early prepared for that the alteration in the financing liability should be evaluated. 
Springtime 2008 the Institute of Health Management and Health Economics at the 
University of Oslo was assigned the responsibility for the evaluation. The evaluation is about 
to be finished by July 31 2009. The project is accomplished by a group existing of Irina 
Bjarkum, Silje Hobbel and Karianne Orderdalen, all master students at the study program 
Health Economics, Policy and Management, and Terje P. Hagen, professor at the Institute of 
Health Management and Health Economics.  
The main problems to be addressed in the project are:  
1) How are the national guidelines implemented at ward levels in the hospitals?  
2) How has the transfer of the financing liability affected the price competition in this 
field?  
3) How has the changes in the financing liability affected the distribution and use of the 
TNF- inhibitors?  
As part of the evaluation linked to the problems 1 and 3, the project group would like to 
accomplish interviews with specialists within rheumatology to get an insight in how the 
guidelines are being used, how well the function and how they possibly could be 
improved. It is desirable to go through with focus group interviews, i.e. interviews with a 
number of specialists from the same ward at the same time. In that way we hope to 
succeed in having a discussion considering the guidelines in a competent clinical 
environment. Wards and individuals will be ensured fully anonymity both during the 
process and in the reporting of the results.  
 69 
We hope you and a selection of specialists at the ward are positive concerning such an 
interview. The master student Karianne Orderdalen will contact you in the next few days 
to arrange time for the interview. An interview guide will be send before the interview 
takes place.  
 
Attachment:  
1. Information letter from the Ministry of Health and Care Services 
2. Project description  
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Appendix II: Interview guide (translated)  
Interview guide 
The intention with this interview is to have various specialists view point concerning the 
national guidelines for TNF- inhibitors, which was published in 2007. On the instructions the 
Ministry of Health and Care Services the undersigned wants to accomplish interviews with 
specialists in rheumatology from different hospitals in Norway and among private 
specialists, to bring out different opinions and viewpoints according to use of these 
guidelines.  
The interview is expected to take about half an hour, and will take place at the hospitals and 
the clinics.   
When it comes to use of supporting materials there will be made use of tape recorder in such 
a way that the interviewer afterwards can go through the interviews for transcription and 
analysis. The interviewee will receive a copy from the interview and the analysis that has 
been made, for acceptance and possible correction.  
Furthermore, it is emphasized that the interview will be confidential, neither name of the 
interviewee nor name of the hospital will be mentioned.  There will be possible to withdraw 
from the interview at any time during the process, in case that by various reasons is 
desirable.  
Finally, there should be mentioned that it will only be the undersigned that has access to the 
data that exists after ended interview. These data will only be used for this purpose, and will 
be deleted after the work with the analysis is ended.  
 
 
 
Yours sincerely,  
Karianne Orderdalen  
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Background information 
Age: 
Education: 
Position: 
Knowledge of the national guidelines 
Do you know about the national guidelines for use of TNF- inhibitors?  
Do you know what authority that has worked out the guidelines? 
- In your opinion, who should work out such guidelines?  
As it is today?  
At a lower administrative level?  
How would you shortly describe the national guidelines? 
Do you think the guidelines are applied (does they have influence in practice)? 
- Why/why not? 
- If not, might that be justified in: 
Allowance for the doctor-patient relationship (being afraid of not fulfill the 
professional responsibility)? 
That the guidelines do not fit into the treatment of the individual patient? 
Other reasons? 
In the guidelines there are made several demands that has to be fulfilled before TNF- 
inhibitors can be prescribed, among others demand for earlier treatment. How do you 
apprehend that these demands are attended to (generally)?  
Contents of the guidelines 
How do you comprehend the scope of the guidelines (long/short)?  
Are they orderly?  
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Are they updated? 
Does they in your opinion inform well about what patient groups they include? 
Use of the guidelines 
How accessible are the guidelines? 
What practical importance do you attach in your daily work these guidelines (great/little)?  
Are there established other arrangements for treatment of TNF- inhibitors in stead of/ in 
addition to (e.g. committees at the hospital or something similar)?  
- In case other arrangements are established, what is the cause of that?  
- Do you think it for instance lack incentives for use of the guidelines?  
Prescription culture  
How are the procedures for the prescription of TNF inhibitors in your clinic3? 
Who can prescribe TNF- inhibitors in your department/clinic? 
In the guidelines it is stated that at least two specialists in rheumatology should sign when 
prescribing TNF- inhibitors. Is this fixed procedure4?  
- Why/ why not (e.g. extra work)5? 
Do you think there are variations in the prescription culture between the regions?  
- Why/ why not? 
- In that case, do you mean that this affects the patient treatment?  
Are other treatment tested before TNF- inhibitors are prescribed in your ward?  
- In that case, what kind? 
                                            
3 Question in the interview guide for private specialists 
4 5Not included in the interview guide for private specialists  
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Progress in prescription 
Would you say that there are more or fewer patients that get these medicaments now than 
before the regional health authorities took over the financing responsibility from June 1 
2006?  
Could you say something about how the prescription practice for TNF- inhibitors was in 
your department/clinic before June 1 2006?  
Can you say something about how the prescription practice for TNF- inhibitors is in your 
department/clinic today?  
Economic considerations 
Do you think that the hospitals6 budgets are affecting the assignment of TNF- inhibitors 
(economic considerations)?  
- Ex.: Will limited polyclinic capacity lead to changed prescription practice?  
Do you think the changes in the financing system have had anything to say for the 
prescription practice in your department/clinic? 
Spreadsheet from “Legemiddelinnkjøpssamarbeidet” (LIS)  
Do you know about the spreadsheet LIS has made for prescribing TNF- inhibitors? 
- In that case, is the spreadsheet used in your daily work? 
- Why/ why not? 
If not, does that have anything to do with the spreadsheet being to time-
consuming? 
Would you use it if it was less time-consuming/simpler to use? 
Do you have any comments to how this spreadsheet could have been 
simplified? 
Remaining questions 
                                            
6 Health enterprises' budgets in the interview guide for private specialists 
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Do you have any comments to changes in the guidelines? 
How do you apprehend the attitude towards the guidelines? 
- At the department? 
- In general? 
Do you have any comments to what have been discussed above or anything you would like 
to add? 
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Appendix III: Invitation to survey (translated) 
Knowledge of the national guidelines for TNF-inhibitors 
The purpose of this survey is to get different specialists views on the national professional 
guidelines for TNF-inhibitors, which was published in 2007. On commission by the Health 
and Care Ministry this survey is sent to specialists in rheumatology, where we hope to bring 
up the different opinions and viewpoints related to the application of these guidelines. The 
survey is expected to take approximately ten minutes. The results from this survey will be 
used in efforts to investigate whether the guidelines for TNF-inhibitors work, and what could 
or should be changed. In addition, it is desirable to find out whether the spreadsheet from the 
“Legemiddelinnkjøpssamarbeidet” (LIS) is used in the initiation of TNF-inhibitors. The 
survey is anonymous. 
 
Thank you! Any comments or questions can be sent to me at:                      
karianne.orderdalen @ studmed.uio.no 
 
Reminder: National guidelines for TNF-inhibitors  
Faculty of Medicine at the University of Oslo is conducting an evaluation of the national 
guidelines for the use of TNF-inhibitors. The evaluation is carried out on behalf of Health 
and Care Ministry. The attached questionnaire takes between 5 and 10 minutes to complete. 
We request an answer within 30. April.  
Sincerely,  
Terje P. Hagen  
Professor 
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Appendix IV: Survey (translated) 
Knowledge of the national guidelines for TNF-inhibitors 
 
The purpose of this survey is to get different specialists views on the national curricular 
guidelines for TNF-inhibitors, which was released in 2007. On assignment from the Health 
and Care Ministry sent this survey to specialists in rheumatology, where we hope to bring up 
the different opinions and viewpoints related to the application of these guidelines. The 
survey is expected to take approx. ten minutes. The results from this survey will be used in 
efforts to investigate whether the guidelines for TNF-inhibitors work, and what could or 
should be changed. In addition, it is desirable to find out whether the sheet from 
“Legemiddelinnkjøpssamarbeidet” (LIS) is used in connection with the initiation of TNF-
inhibitors. The survey is anonymous.  
 
1) Do you have knowledge of the national curricular guidelines for TNF-inhibitors?  
 
Yes  
No  
 
2) Do you have knowledge of the agency that has prepared the guidelines? Mention the 
name of the agency.  
 
3) Who should develop such guidelines?  
 
As today  
A lower administrative level  
Other  
 
4) How would you briefly describe the national guidelines for TNF-inhibitors?  
   
5) Do you think the guidelines are followed (they have influence in practice)?  
 
Yes  
No  
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Do not know  
 
6) If no, what is not followed up?  
  
7) How do you comprehend scope of the guidelines?  
 
To short  
To long  
Long enough 
 
8) Are they orderly?  
 
Yes  
No  
Do not know  
 
9) Are they updated?  
 
Yes  
No  
Do not know  
 
10) Does they in your opinion inform well about what patient groups they include?  
 
Yes  
No  
Do not know  
 
11) Are the guidelines accessible?  
 
Yes  
No  
12) Where did you get the guidelines from the first time?  
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They were sent to me  
Found them myself on the web  
Do not know  
Other, please specify here  
 
13) What practical importance do you attach in your daily work these guidelines?  
 
Little  
Medium  
Great 
Do not know  
 
14) Are there other arrangements established for treatment with TNF-inhibitors instead/in 
addition? (An example of this can be their own committees, or in the hospital/clinic)  
 
Yes  
No  
 
15) If other arrangements are established, what is the cause of that? 
 
16) Who can prescribe TNF-inhibitors with you?  
 
None  
Only the specialists in rheumatology  
All doctors  
Other, please specify here  
 
17) In the guidelines it is indicated that at least two specialists in rheumatology should sign 
when prescribing TNF inhibitors. Is this fixed procedure?  
 
Yes  
No  
Do not know  
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18) Do you think there are variations in prescription cultural between the regions?  
 
Yes  
No  
Do not know  
 
19) Are other treatment tested before TNF-inhibitors can be prescribed in your ward?  
 
Yes  
No  
Do not know  
 
20) Would you say there are more or fewer patients receiving these drugs now than before 
the regional health enterprises took over financing responsibility from June 1 2006?  
 
Several  
Fewer  
No change  
Do not know 
 
21) Do you know about the spreadsheet Legemiddelinnkjøpssamarbeidet (LIS) has made for 
prescribing TNF inhibitors?  
 
Yes  
No  
Do not know  
 
22) Is the spreadsheet used in your daily work?  
 
Often  
Fairly often  
Seldom  
Never  
I do not know about the spreadsheet  
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23) Do you have suggestions for changes that should have been made in the guidelines?  
 
24) Age?  
 
20-29  
30-39  
40-49  
50-59  
60-69  
Other, please specify here  
 
25) Gender?  
 
Man  
Female  
 
26) County you practice in? 
 
 
  
